Novartis Research and Development
MIJ821
Clinical Trial Protocol CMIJ821X2201
A multi -center, randomized, subject and inv estigator -
blinded, placebo -controlled, activ e comparator, parallel-
group proof of concept study  to ev aluate the efficacy , 
safety , tolerability , and pharmacokinetics of MIJ821 in 
patient swith treatment -resistant depression
Document type: Amended Protocol Version
EUDRACT number: 2018 -003002 -12
Version number: 02
(Clean )
Clinical Trial Phase: II
Release date: 10-Jul-2019
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template version 1.0 dated 01 -Dec-2017
Novartis Confidential Page 2
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  procedures. Note: The SOM will not be a part of the Clinical Study  Report.
Novartis Confidential Page 3
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Table of contents
Site Operations Manual (SOM) ........................................................................................... 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 18
1.1 Background ............................................................................................................ 18
1.2 Purpose .................................................................................................................. 18
2Objectives and endpoints ................................................................................................... 19
3Study  design ................................................................
...................................................... 20
4Rationale ............................................................................................................................ 22
4.1 Rationale for stud y design ..................................................................................... 22
4.2 Rationale for dose/r egimen and duration of treatment
.......................................... 22
4.3 Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 23
4.4 Purpose an d timing of interim anal yses/design adaptations .................................. 24
4.5 Risks and benefits ................................
.................................................................. 24
4.5.1 Blood sample volume ............................................................................ 26
5Population .......................................................................................................................... 27
5.1 Inclusion criteria ................................................................
.................................... 27
5.2 Exclusion criteria ................................................................................................... 28
6Treatment ........................................................................................................................... 30
6.1 Study  treatment ...................................................................................................... 30
6.1.1 Investigational and control drugs .......................................................... 30
6.1.2 Additional study  treatments .................................................................. 30
6.1.3 Treatment arms/group ........................................................................... 30
6.2 Other treatment(s) .................................................................................................. 31
6.2.1 Concomitant therap y ............................................................................. 31
6.2.2 Prohibited medication
........................................................................... 31
6.2.3 Restriction for study  subjects ................................
................................ 32
6.3 Subject numbering, treatment assignment, randomization .................................... 32
6.3.1 Subject numbering ................................................................................ 32
Commercially Confidential Information
Novartis Confidential Page 4
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6.3.2 Treatment assignment, randomization .................................................. 32
6.4 Treatment blinding ................................................................................................. 32
6.5 Dose escalation and dose modification.................................................................. 34
6.6 Additional treatment guidance ................................
............................................... 35
6.6.1 Treatment compliance ........................................................................... 35
6.6.2 Recommended treatment of adverse events .......................................... 35
6.6.3 Emergency  breaking of assigned treatment code .................................. 35
6.7 Preparation and dispensation ................................................................................. 36
7Informed consent procedures ............................................................................................ 36
8 Visit schedule and assessments
......................................................................................... 37
8.1 Screening ................................
............................................................................... 43
8.1.1 Information to be collected on screening failures ................................. 43
8.2 Subject demographics/other baseline characteristics............................................. 43
8.3 Efficacy ................................................................
.................................................. 43
8.3.1 Montgomery  Asberg Depression Rating Scale ..................................... 43
8.3.4 Appropriatenes s of efficacy  assessments .............................................. 45
8.4 Safety  / Tolerability ............................................................................................... 45
8.4.1 Laboratory evaluations .......................................................................... 46
8.4.2 Electrocardiogram (ECG) ..................................................................... 47
8.4.3 Pregnancy  and asse ssments of fertility ................................................. 47
8.5 Additional assessments.......................................................................................... 48
8.5.1 Clinical Out come Assessments (COAs) ............................................... 48
8.5.2 Pharmacokinetics ................................
.................................................. 51
9Study  discontinuation and completion .............................................................................. 53
9.1 Discontinuation ...................................................................................................... 53
9.1.1 Discontinuation of study  treatment ....................................................... 53
9.1.2 Withdrawal of informed consent ........................................................... 54
9.1.3 Lost to follow -up................................................................................... 54
9.1.4 Study  stopping rules
.............................................................................. 55
9.1.5 Early study termination by the sponsor ................................................. 55
9.2 Study  completion and post -study  treatment .......................................................... 55
10Safety  monitoring and reporting ........................................................................................ 56
10.1 Definition of adverse events and reporting requirements ...................................... 56
10.1.1 Adverse events ...................................................................................... 56
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 5
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
10.1.2 Serious adverse events .......................................................................... 57
10.1.3 SAE reporting........................................................................................ 58
10.1.4 Pregnancy  reporting .............................................................................. 59
10.1.5 Reporting of stud y treatment erro rs including misuse/abuse ................ 60
10.2 Additional Safety  Monitoring ................................
................................................ 60
10.2.1 Liver safety  monitoring ......................................................................... 60
10.2.2 Renal safet y monitoring ........................................................................ 61
10.2.3 Prospective suicidality  assessment ........................................................ 61
10.2.4 Data Monitoring Committee ................................................................. 62
11Data Collection and Database management ...................................................................... 62
11.1 Data collection................................................................
....................................... 62
11.2 Database management and quality  control ............................................................ 62
11.3 Site monitoring ...................................................................................................... 63
12Data analy sis and statistical methods ................................................................................ 64
12.1 Analy sis sets ................................................................
.......................................... 64
12.2 Subject demographics and other baseline characteristics...................................... 64
12.3 Treatments ................................................................
............................................. 64
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 64
12.4.1 Definition of primary  endpoint(s) ......................................................... 65
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 65
12.4.3 Handling of missing values/censoring/discontinuations ....................... 65
12.4.4 Sensitivity  and Supportive anal yses...................................................... 65
12.5 Analy sis of secondary  endpoints ........................................................................... 66
12.5.1 Efficacy  and/or Pharmacody namics endpoint(s) .................................. 66
12.5.2 Safety  endpoints .................................................................................... 67
12.5.3 Pharmacokinetics .................................................................................. 68
12.5.4 PK/PD relationships .............................................................................. 69
12.5.5 Patient reported outcomes ..................................................................... 69
12.6 Analy sis of exploratory  endpoints ......................................................................... 69
12.6.3 Other Exploratory  Endpoints ................................................................ 69
12.7 Interim anal yses..................................................................................................... 69
12.8 Sample size calculation.......................................................................................... 70
12.8.1 Primary  endpoint(s) ................................
............................................... 70
12.8.2 Secondary  endpoint(s) ........................................................................... 70
13Ethical considerations and administrative procedures ...................................................... 71
Commercially Confidential Information
Novartis Confidential Page 6
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
13.1 Regulatory and ethical compliance ........................................................................ 71
13.2 Responsibilities of the investigato r and IRB/ IEC.................................................. 71
13.3 Publication of study  protocol and results ............................................................... 71
13.4 Q uality  Control and Quality  Assurance ................................................................. 71
14Protocol adherence ................................................................
............................................ 72
14.1 Protocol Amendments ........................................................................................... 72
15References ......................................................................................................................... 73
16Appendices ........................................................................................................................ 75
16.1 Appendix 1: L iver event and Laboratory  trigger Definitions and Follow-up 
Requirements ................................................................
......................................... 75
16.2 Appendix 2: Specific Renal Alert Criteria and Actions and Event Follow- up...... 78
List of tables
Table 2-
1 Objectives and related endpoints .......................................................... 19
Table 6-1 Overview of study  medication .............................................................. 30
Table 6-
2 Blinding and unblinding plan................................
................................ 34
Table 8-1 Assessment Schedule ............................................................................ 38
Table 8
-2 Laboratory  Assessments ........................................................................ 46
Table 10
-1 Guidance for capturing the study  treatment errors i ncluding 
misuse/abuse ......................................................................................... 60
Table 16
-1 Liver Event and Laboratory  Trigger Definitions .................................. 75
Table 16-
2 Follow Up Requirements for L iver Events and Laboratory  Triggers ...76
Table 16-
3 Specific Renal Alert Criteria and Actions ............................................. 78
Table 16-4 Renal Event Follow Up ......................................................................... 79
List of figures
Figure 3 -
1 Study  design .......................................................................................... 21
Commercially Confidential Information
Novartis Confidential Page 7
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
List of abbreviations
AE adverse event
ALT alanine aminotransferase
ANCOVA analysis of covariance
APA American Psychological Association
AR(1) first-order autoregressive
AST aspartate aminotransferase
AUC Area Under the Curve
AUCinf Area Under the Curve from time zero to infinity
AUClast area under the curve from time zero to time of last measurable concentration
BP Blood Pressure
BRMS Bech- Rafaelsen Melancholia Scale
BUN blood urea nitrogen
C-SSRS Colum bia Suicide Severity Rating Scale
CADSS Clinical -Administered Dissociative States Scale
CFR U.S. Code of Federal Regulation s
CGI Clinical Global Impression
CGI-I Clinical Global Impression of Improvement
CGI-S Clinical Global Impression of Severity
CK creatinine kinase
CL apparent total body clearance of the drug from plasma
cm centimeter(s)
Cmax maximum plasma drug concentration
CMO&PS Chief Medical Office & Patient Safety
CNS Central Nervous Sy stem
CO 2 carbon dioxide
CRA Compliance and Regulatory Affairs
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CSR Clinical study report
CTC Common Toxicity Criteria
CV coefficient of variation
DAE Dissociative adverse event
DAR Dose Administration Record
DDE Direct Data Entry
DES Dissociative Experiences Scale
DNA Deoxyribonucleic Acid
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
ECG Electrocardiogram
eCRF electronic Case Report Form
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 8
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
EDC Electronic Data Capture
EMA European Medicines Agency
EU Europe
FAS Full Analysis Set
FIH First in Human
FSH Follicle Stimulating Hormone
GASE Generic Assessment of Side Effects
GCP Good Clinical Practice
GCS Global Clinical Supply
GGT Gamma -glutam yl transferase
GLP Good Laboratory Practice
h Hour
HAM-A Hamilton Anxiety Rating Scale
HIV human immunodeficiency virus
hsCRP High Sensitivity C -Reactive Protein
IB Investigator's Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IL Interleukin
IN Investigator Notification
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent -to-Treat
IUD intrauterine device
IUS intrauterine system
kg killogram(s)
KMDRS Koukopoulos Mixed Depression Rating Scale
KR Kenward -Roger
LC-MS/MS Liquid Chromatography -tandem Mass Spectrometry
LDH lactate dehydrogenase
MADRS Montgomery  Asberg Depression Rating Scale
MDD Major Depressive Disorder
MDE Major Depressive Episode
MedDRA Medical dictionary for regulatory activities
mg milligram (s)
mL milliliter(s)
MMDC Melancholia and Mixed Depression Diagnostic Checklist
MMRM Mixed -effects Model for Repeated Measures
MTI Maudsley Treatment Inventory
Commercially Confidential Information
Novartis Confidential Page 9
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
NIRT Novartis Interactive Response Technology
NMDA N- methyl-D-aspartate
NOEL No Observable Effect Level
PD pharmacodynamic(s)
PHQ Patient Health Questionnaire
PK pharmacokinetic(s)
PPS per protocol set
QMS Quality Management System
QTcB QT interval corrected by Bazett's formula
QTcF QT interval corrected by Fridericia’s formula
RBC red blood cell(s)
RoW Rest of World
SAE serious adverse event
SCID -5(-RV) Structured Clinical Interview for DSM -5 (Research Version)
SD standard deviation
SMPI Sydney  Melancholia Prototype Index
SMQ Standardized MedDRA Query
SOM Site Operations Manual
STS Suicidality Tracking Scale
SUSAR Suspected Unexpected Serious Adverse Reactions
T1/2 Elimination half -life
Tmax time to reach maximum plasma concentration
TRD Treatment -Resistant Depression
TSH thyroid- stimulating hormone
ULQ Upper L imit of Quantification
UN unstructured
US United States
Vz apparent volume of distribution during terminal phase
WBC white blood cell(s)
WHO World Health Organization
WOC Withdrawal of consent
β-hCG Beta- Human Chorionic Gonadotropin
Novartis Confidential Page 10
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject 
Cohort A specific group of subjects fulfilling certain criteria
Control drug A study drug (active or placebo) used as a comparator to reduce 
assessment bias, preserve blinding of investigational drug, assess internal 
study validity, and/or evaluate comparative effects of the investigational 
drug
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 1 00 
mg once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems and cli nical laboratory interfaces. 
EDC includes the use of Electronic Case Report Forms (eCRFs) which 
are used to capture data transcribed from paper source forms used at the 
point of care
End of the clinical trial The end of the clinical trial is defined as the last visit of the last subject or 
at a later point in time as defined by the protocol
Enrollment Point/time of subject entry into the study at which informed consent must 
be obtained
Epoch Interval of time in the planned conduct of a study. An epoch is associated 
with a purpose (e.g. screening, randomization, treatment, follow -up) which 
applies across all arms of a study.
eSource eSource Direct Data Entry (DDE) refers to the capture of clinical study 
data electronically, at the point of care. eSource combines source 
documents and case report forms (eCRFs) into one application, allowing 
for the real time collection of clinical trial information to sponsors and other 
oversight authorities, as appropriate.
Healthy volunteer A person with no known significant health problems who volunteers to be 
a study participant 
Investigational 
drug/treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Part A single component of a study  which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients with 
established disease and in those with newly -diagnosed disease.
Patient An individual with the condition of interest for the study
Personal data Subject information collected by the Investigator that is transferred to 
Novartis for the purpose of the clinical trial. This data includes subject 
identifier information, study information and biological samples
Randomization 
numberA unique identifier assigned to each randomized subject
Screen Failure A subject who did not meet one or more criteria that were required for 
participation in the study
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Novartis Confidential Page 11
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Study treatment Any single drug or combination of drugs or intervention administered to 
the subject as part of the required study procedures
Study treatment 
discontinuationWhen the subject permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any re ason; 
may or m ay not also be the point/time of study discontinuation
Subject A trial participant (can be a healthy volunteer or a patient)
Subject number A unique number assigned to each subject upon signing the informed 
consent. This number is the defin itive, unique identifier for the subject and 
should be used to identify the subject throughout the study for all data 
collected, sample labels, etc.
Treatment arm/group A treatment arm/group defines the dose and regimen or the combination, 
and may consis t of 1 or more cohorts.
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of consent 
(WoC)Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer and does not allow any further 
collection of personal data
Novartis Confidential Page 12
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Commercially Confidential Information
Novartis Confidential Page 13
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Commercially Confidential Information
Novartis Confidential Page 14
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Commercially Confidential Information
Novartis Confidential Page 15
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Protocol sum mary
Protocol number CMIJ821X2201
Full Title A multi-center, randomized, subject and investigator -blinded, placebo -
controlled, active comparator, parallel -group proof of concept study  to evaluate 
the efficacy , safety, tolerability, and pharmacokinetics of MIJ821 in patients 
with treatment -resistant depression
Brief title Study of eff icacy and safety of MIJ821 in treatment -resistant depression 
patient s.
Sponsor and 
Clinical PhaseNovartis
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe main purpose of this non-confirmatory  study is to evaluate the clinical 
responses of MIJ821 in patient s suffering from treatment -resistant depression 
assessed by the Montgomery  Åsberg Depression Rating Scale 
(Montgo meryandAsberg 1979 ).
Furthermore it is expected that this stud y will guide the future clinical trials with 
MIJ821 in treatment of resistant depression.
Primary 
Objective(s)The primary  objective of this study  is to assess the efficacy  of MIJ821 in 
treatment -resistant depression at 24 hours after the start of infusion . 
Themeasure will be conducted through MADRS total score, 24 hours after the 
start of first infusion compared to the baseline assessment.
Secondary 
ObjectivesTo assess the efficacy of MIJ821 in treatment -resistant depression by 1) 
evaluating the percentage of treatment response (>50% improvement in 
MADRS) at 24 hours, 48 hours (if applicable) and 6 weeks after the start of first 
infusion 2) evaluating the percentage of remission (MADRS <7) at 24hours, 
48 hours (if applicable )and 6 weeks after the start of first infusion ; 3) evaluating 
the CGI -I and CGI -S scores at 24 hours, 48 hours (ifapplicable ), and 6 weeks
after the start of first infusion .
To assess the impact of MIJ821 on suicidality .
To assess the MIJ821 pharmacokinetics in plasma .
To assess the most effective dose and dosing regimen.
To assess the safety and tolerability of weekly and bi-weekly infusions of 
MIJ821.
To assess the efficacy in melancholic subtype of depression .
Toassess the risk of mania induction .
To assess the efficacy of MIJ821 for mixed mood sy mptoms.
To assess the efficacy of MIJ821 for anxiety s ymptoms.
To assess the impact of mixed mood symptoms, melancholia, and anxiety as 
predictors of treatment response to MIJ821.
Novartis Confidential Page 16
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Study design This is a m ulti-center, randomized, parallel group, active comparator, placebo -
controlled study . The study  will enroll approximately 66 subjects presenting 
with Treatment -Resistant Depression. The study  consists of a screening and 
baseline period (D-28 to D-1), a treatment period (D1 to D36) and a 5 week 
follow -up period with an end of study  visit on Day 71. The maxi mum duration 
of the study including screening i s approximately 14 weeks.
Population Male and female subjects, 18 to 65 years (inclusive), diagnosed with 
Treatment -Resistant Depression. Eligible subjects may come from either an 
inpatient or outpatient treatment setting.
Key Inclusion 
criteriaSigned informed consent must be obtained prior to participation in the
study.
Male and female subjects, 18 to 65 years of age (inclusive) at screening.
Subject is in a DSM -5 defined major depressive episode at the time of
screening
Subject obtains a Montgomery -Åsberg Depression Rating Scale
(MADRS) score ≥ 24 at screening and baseline
Failure to response to two or more prior antidepressant treatments ,
where two failed treatments are of two different antidepressants, with
adequate dose and duration ( ≥ 8 weeks duration, doses defined per
agent) for the current or prior major depr essive episode, as identified by
the Maudsley Treatment Inventory, and prior psychiatric histor y,
assessed by the investigator, and further documented by medical records
and/or third party report (family , friends, clinician -treaters) where
available
At lea st one prior clinical depressive episode (recurrent major depressive
disorder), as identified by prior psychiatric histor y assessed by the
investigator, and further documented by medical records and third party
report (family , friends, clinician -treaters) where available.
Key Exclusion 
criteriaAny current diagnosis of bipolar disorder, schizophrenia, or
schizoaffective disorder .
Current alcohol or substance use disorder (including marijuana and
prescribed amphetamine) meeting DSM -5 criteria ,within the pa st month
at baseline .Nicotine and caffeine use disorders are not considered as
exclusionary substances.
Prior suicidality caused by or associated with ketamine, as identified by
prior ps ychiatric history assessed by the investigator, and augmented by
medical records and third party report (family , friends, clinician -treaters)
where available.
Acute serious and/or imminent suicidal ideation and/or intent within the
prior 2 weeks, or any suicide attempt within the prior 4 weeks at
screening. Mild to moderate suicidal ideation, using the Sheehan Suicidal
Ideation Scale and not meeting the above definition, is not an exclusion
criterion.
Use of other investigational drugs within 30 days or 5 half -lives of
randomization , whichever was longer; or longer if requi red by local
regulations.
Current pregnancy or lactation.
Positive HIV, Hepatitis B or C test.
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre -treatment
baseline.
Novartis Confidential Page 17
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Study treatment Patients who meet the eligibility criteria at screening and baseline will be 
randomized to one of the six treatment arms in the European countries (only 
five arms in the USA as there is no ketamine arm)
Efficacy 
assessmentsMontgomery  Åsberg Depression Rating Scale at 24 hours post -dose
% treatment response (>50% improvement in MADRS) at 24 hours, 48
hours (if applicable) , and 6 weeks after the start of first infusion
% treatment remission (MADRS<7) at 24 hours, 48 hours (if applicable) ,
and 6 weeks after the start of first infusion
CGI-S and CGI -I scores at 24 hours, 48 hours (if applicable) , and 6
weeks after the start of first infusion Sheehan Suicidality Tracking Scale
score changes from baseline at 24 hours, 48 hours (if applicable) , and 6
weeks after the start of first infusion
Montgomery  Åsberg Depression Rating Scale score at 6 weeks after the
start of first infusion
Other 
assessments
Pharmacokinetic 
assessmentsMIJ821 pharmacokinetics in plasma
Key safety 
assessmen tsAdverse event monitoring, Phy sical examinations, Monitoring of laborator y 
markers in blood and urine, ECGs.
Data analysis The change from baseline in the total MADRS score at 24 hours after single 
dose administration will be analy zed using an analy sis of covariance 
(ANCOVA) model with treatment as a group factor and baseline MADRS score 
as a covariate . 
Key words Treatment -Resistant Depression; Major Depressive Episode; Major 
Depressive Disorder
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 18
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
1 Introduction
1.1 Background
Treatment -resistant depression (TRD) is defined as a failure to respond to at least two different 
antidepressants for a period longer than 4-6 weeks at the maximum recommended dose 
(Sackeim 2001). One-third or more of patients suffering from unipolar depressive illness, 
defined in DSM -5 as major depressive disorder (MDD), fail to respond acutely  to antidepressant 
treatment of adequate dose and duration ( Rush et al 2006). Even more sub jects, the majorit y in 
fact, fail to maintain long-term response to standard antidepressants 
(Rush et al 2006).  
Further, suicide is a major harm with depressive illness, 
with depression being present in the 
vast majori ty of persons who commit suicide (Isometsä 2001). Most antidepressants have a few 
weeks delay  in symptom benefit, during which time individuals can be at suicidal risk.
Ketamine, which is a NMDA receptor antagonist, has been shown to be effective in TRD in 
off-label research, but is limited by psychotomi metic side effects (Katalinic et al 2013
; 
Browne andLucki2013). Further ketamine has been shown to be rapid -acting and reduce 
suicidality  (Katalinic etal2013
). The efficacy  of ketamine provides the rationale for targeting 
NMDA receptor inhibition as a rapid -onset antidepressant mechanism. 
1.2 Purpose
The main purpose of this non-confirmatory  study is to evaluate the clinical responses of MIJ821 
in subjects suffering from treatment -resistant depression assessed by the Montgomery  Åsberg 
Depression Rating Scale (Montgomery andAsberg 1979 ), a validated and widel y employ ed 
method in depression trials.
Furthermore, it is expected that this study  will guide the future clinical trials with MIJ821 in 
patients with treatment resistant depression.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 19
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To assess efficacy of MIJ821 in treatment -
resistant depression.Montgomery  Asberg Depression Rating Scale
total score at 24 hours after the start of the
infusion compared to the baseline
assessment .
Secondary objective(s) Endpoint(s) for secondary objective(s)
To assess risk of mani a induction. Young Mania Rating Scale at 24 hours, 48
hours (if applicable ) and 6 weeks post -dose.
To assess efficacy in the melancholic
subtype of depression.Bech- Rafaelsen Melancholia and CORE scale
change from baseline to 24 hours, 48 hours (if
applicable )and 6 weeks post -dose.
To assess safety  and tolerability,
especially dissociative side effects.Incidence of adverse event
Dissociative rating scales (Clinician -
Administered Dissociative States Scale, and
Dissociative Experiences Scale) change from
baseline to 24 hours, 48 hours (if applicable )
and 6 weeks post-dose.
To assess most effective dose and dosing
regimen.Montgomery  Åsberg Depression Rating Scale
score at 6 weeks.
To assess MIJ821 pharmacokinetics in
plasma.PK properties of MIJ821 in plasma described
by AUClast , AUC0 -24h, Cma x, Tmax
(parameters not limited)
To assess impact of MIJ821 on suicidality. Sheehan Suicidality Tracking Scale changes
from baseline at 24 hours, 48 hours (if 
applicable ), and 6 weeks after the start of first 
infusion .
To assess efficacy of MIJ821 on measures
of response and remission% treatment response (>50% improvement in
MADRS) at 24 hours, 48 hours (if applicable ),
and 6 weeks after the start of first infusion .
% treatment remission (MADRS<7) at 24
hours, 48 hours (if applicable ), and 6 weeks
after the start of first infusion
CGI-S and CGI -I scores at 24 hours, 48 hours
(if applicable ), and 6 weeks after the start of
first infusion
To assess efficacy of MIJ821 for mixed
mood sy mptoms.Koukopoulos Mi xed Depression Rating Scale
change from baseline to 24 hours, 48 hours,
and 6 weeks after the start of first infusion .
To assess efficacy of MIJ821 for anxiety
symptoms.Hamilton Anxiety Scale change from baseline
to 24 hours, 48 hours (if applicable ), and 6
weeks after the start of first infusion
Novartis Confidential Page 20
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Objective(s) Endpoint(s)
To assess impact of mixed mood
symptoms, melancholia, and anxiety as
predictors of treatment response to
MIJ821.Regression model effect sizes (odds ratios) for
Hamilton Anxiety Scale, Bech -Rafaels en
Melanch olia Scale, and Koukopoulos Mixed
Depression Rating Scale as predictors, with
MADRS treatment response as outcome, at
24 hours, 48 hours (if applicable ), and 6
weeks after the start of first infusion .
Exploratory objective(s) Endpoint(s) for exploratory objective(s)
3 Study  design
This is a non-confirmatory , multi- center, 6-treatment arm in the European countries and 
5-treatment arm in the USA (no ketamine arm), randomized, subject and investigator blinded,
parallel group, placebo controlled study  in treatment -resistant depression patients. The study
will randomiz e approximately 66 Subjects and while the study  design utiliz es an outpatient visit
schedule, the study allows for the inclusion of subjects seeking treatment for their disease from
both an 'inpatient'
or 'outpatient' clinic setting.
Ascreening period of maximum 4 weeks will be used to assess eligibility . Patients who meet 
the eligibility  criteria at screening will proceed tobaseline evaluations on Day-1 or Day 1. 
Allbaseline safety  evaluation results must be available prior to randomization. At the baseline 
visit, eligible subjects will be randomized to one of the treatment arms . Randomiz ed subjects 
will enter a 36-day treatment period, receiving at each treatment visit, a 40-minute infusion 
with a safety  observation period of 2-
4 hours (i.e. a minimum of 2 hours) post the start of 
Commercially Confidential Information
Novartis Confidential Page 21
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
infusion. If the subject reports nodissociative s ymptoms and no suicidal s ymptoms, the subject 
will be allowed to leave the clinical treatment setting. Visits to assess efficacy  and safet y are 
scheduled at 24 hours, 48 hours (if applicable ) and every  week during the treatment period. 
If48 hour visit (V103) is conducted , then all assessments should be completed. Theassessment 
to address the primary  objective will be perform ed at 24 hour post-dose. Safety assessments 
will include phy sical exa minations, ECGs, vital signs, standard clinical laboratory  evaluations 
(hematology , blood chemistry , and urinal ysis), adverse event and serious adverse event 
monitoring. At the conclusion of the treatment period (Day  1 - Day 36), subjects will enter a 
5-week follow up period consisting of two follow visits approximately  1 week (Day 43) and
3weeks (Day  57) after the last study  drug administration and an end of study  completion visit
(Day  71) The total duration for each subject in the study  is maximum 14-weeks including
screening and baseline. No interim analysis is planned. The study  design is summarized in
Figure 3-1below for the European countries (same study  design without the ketamine arm in
the USA).
Figure 3
-1 Study  design
Commercially Confidential Information
Novartis Confidential Page 22
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
4 Rationale
4.1 Rationale for study  design
The design of this study  has been selected to adequately  assess the primary  objective and follow the 
similar design of trials for American Psychiatric Association (APA) treatment guidelines for 
depress ion(Practice guideline forthe treatment of patients with major depressive disorder 2010)
The rationale and justification for the key  elements of the study  design are as follows:
Safety  of administration of MI J821 is supported by  toxicology  studies (i.e. 6- week GL P
studies) and b y results from a study in health y volunteers (MI J821X2101).
Selection of ketamine 0.5 mg/kg IV infusion is a standard dose shown to have
antidepressant effects ( Garay et al 2017 ).
Randomization to parallel groups controls for confounding factors and allows for more
valid cause judgments.
Blinding with placebo control limits effects of expe ctation bias or measurement bias.
The entire treatment period (36 days) can be conducted in anoutpatient or inpatient treatment 
setting. B oth settings are commonly used in the treatment of depression and are appropriate for 
the purpose of the study . The inpatient and outpatient setting in this study  includes a frequent 
v
isit schedule (weekl y). As the outpatient setting may increase the risk of subject suicidality , 
weekl y collections of information about the suicidality risk are implemented.
For the primar y objective, the efficacy  will be determined using the MADRS 
(Montgomery andAsberg 1979) which is a standard for the evaluation of a major depressive 
episode.
4.2 Rationale for dose/regimen and duration of treatment
Commercially Confidential Information
Novartis Confidential Page 23
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
The use of placebo saline solution is to provide a comparison group for an unbiased collection 
and assessment of safet y and tolerability  data.
Ketamine is included primarily  for assay  sensitivity  andfor comparison of side effects. 
Ketamine is known to be effective with large effect sizes for severe depressive episodes, and it 
also has high rates of dissociative side effects in 20-30% of subjects, often of moderate to 
marked severit y. It also can caus e manic episodes, mixed states, and suicidal or aggressive 
reactions in a small minority  of persons. A single subanesthetic dose of intravenous ketamine 
consistently  decreases symptoms of depression in subjects with treatment -resistant depression 
in a rapid (within hours), robust (across many symptoms of depression) and relativel y sustained 
(typically , 7–14 days) manner (Berman et
al2000 ; Cusin et al 2017 ).Repeated doses 
(six infusi ons over the course of several weeks) have shown promise from an efficacy  and safet y 
standpoint (AanhetRotet al 2010
). The efficacy  of two times versus three times a week 
intravenous ketamine in subjects with treatme nt-resistant depression in sustaining the initial 
antidepressant effects was evaluated. Both doses (0.5 and 0.75 mg/kg) were significantly 
superior to placebo in treating depression symptoms and the transient dissociative side effects 
attenuated with repea t dosing (Singh et
al2016). One study  examined the benefits of a fixed 
course of 4 once -
weekl y ketamine sessions (0.5 mg/kg IV) as continuation phase treatment in 
5 patients who had remitted after acute phase treatment . All 5 patients maintained improvemen t 
during the continuation phase (Krystal et al 1994)
.
To limit any dissociative and psychomimetic side effects, the limiting dose for Ketamine 
infusion is at 40 mg/infusion for patients o ver 80 kg .
Commercially Confidential Information
Novartis Confidential Page 24
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
4.4 Purpose and timing of interim analy ses/design adaptations
4.5 Risks and benefits
There is no expected benefit for subjects participating in the study . However, in instances of 
documented TRD, participants may benefit from receiving effective antidepressant therapy  to 
treat the MDD.
The risks of participati ng in the study  include those identified in the clinical studies with MIJ821, 
those associated with IV infusion and those associated with blood sampling. The risk to subjects 
in this trial may be minimized by compliance with the eligibility  criteria, speci fic procedures 
done by  qualified personnel, study  stopping rules as well as close clinical monitoring.
Subjects will  be observed for 2-4hours 
(i.e. a minimum of 2 hours) after the start ofinfusion . If they have no dissociative symptoms 
and no suicidal symptoms after the observation period, they can leave the clinical treatment 
setting. If investigators judge that subjects have anydissociative symptoms , subjects will be 
monitored in the clinic unti l the dissociative sy mptoms resolve and/or extended stay overnight, 
or longer based on investigator judgment. If suicidal symptoms are present to a moderate to 
severe degree, either based on rating scales or investigator judgment, and such symptoms persist 
throughout the above 2-4 hours monitoring period, investigators may consider extending stay 
ofsubjects at least overnight. If suicidal symptoms are mild, either based on rating scales or 
investigator judgment, the investigator's judgment can be used to allow the subject to leave the 
clinical setting, but in that case arrangements should be made such that family  members or 
friends are present with the subject for at least 24 hours. If such arrangements cannot be made, 
the subject may have extended stay atleast overnight. If needed, an additional overnight stay 
beyond the first infusion’s baseline and V101 is permissible.
Women of child bearing potential and sexually  active males must be informed that taking the 
study  treatment may  involve unknown risks to the fetus if pregnancy  were to occur during the 
study , and agree that in order to participate in the study  they must adhere to the contraception 
requirements outlined in the exclusion criteria. If there is any  question that the subject will not 
reliably  comply , he/she should not be entered or continue in the study .
Sexually  active males must be informed of the requirement to wear a condom for the followin g 
reasons:
Prevent pregnancy  in a female partner AND
Present delivery  of investigational drug via seminal fluid to their partner as study
treatment may  involve unknown risks to the fetus if pregnancy  were to occur.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 25
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Given that MI J821 may  impair the mental or phy sical abilities required for the performance of 
dangerous potential tasks such as driving a car or operating machinery , subjects should be 
advised about these potential risks. If the subject is feeling drunk or dizzy  or if he/she 
experiences visual disturbances, hallucinations, or euphoric mood, then the subjects should not 
drive, use machines or perform any other tasks that require his/her attention and good 
coordination. In that case, the subject should be hospitalized until resolution of these events. 
These judgments will be made b y the investigators, not the subjects. 
In general, hypersensitivity  or infusion reaction can manifest with itching, flushing, headache, 
nausea, vomiting, hypotension, urticaria, bronchospasm, or angioedema. In the event of a 
hypersensitivity  reaction, stop the infusion immediately .
Subjects participating to the MIJ821X2201 study  will be provided with a subject information 
card that they  would car ry with them at all time and as long as they  are treated with MI J821 or 
ketamine. This card will warn of potential interaction with CYP3A4, CYP2B6, CYP2C8, 
CYP2C19, or CYP2D6 inducers or inhibitors and should be presented to every  
physician/healthcare provider the subject may consult to inform them about potential drug 
interactions. It is also important that the subject is asked to contact his/her study  doctor to inform 
him/her of his/her status as well as to discuss any treatment recommendations. As a gene ral 
precaution with all investigational drugs, sites should have the capacit y of managing acute 
hypersensitivity  reactions (or similar emergency situations) or be prepared to transfer the 
subject urgentl y, should these reactions emerge.
Benefits of ketamin e have been shown for rapid improvement of depressive symptoms within 
1-2 days, which persists 
up to 3-4 weeks after one dose. This improvement has been shown
mainly  with intravenous infusion of 0.5 mg/kg ketamine over 40 minutes (Katal inicet al 2013
).
Twoopen -studies (Price et al 2009, Thakurta et al 2012
) also have suggested that ketamine may
be an appropriate treatment to rapidly  reduce acute suicide risk in de pressed patients. Benefits
have 
been shown also recentl y with intranasal administration of esketamine. These benefits
occur for acute depressive symptoms, and have not been studied or proven for long-term or
maintenance administration. The amount of benefit seen acutel y meets or exceeds the effect
sizes seen with standard antidepressants. Some studies report such benefit in treatment -resistant
depression, with patients who have failed multiple prior antidepressant trials. Such benefit has
been seen with bot h bipolar and unipolar depression.
Most of the research conducted using 
subanaesthetic doses of ketamine has shown 
psychotomimetic and neurops ychological adverse effects: general psychiatric symptoms, 
agitation, dissociative symptoms and manic symptoms. These effects have mostly  been 
restricted to the time of administration, disappearing completely by 60 minutes afterward. 
Other adverse events experienced by patients include feelings of intoxication and lowered 
inhibitions, confusions, decreased concentrati on and perceptual disturbances. Most of these 
Commercially Confidential Information
Novartis Confidential Page 26
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
impairments were only apparent during the infusions, and none persisted longer than 2 hours 
after the beginning of the infusions.
There have been not many significant physical adverse event reported in studies of low-dose 
ketamine (used as an antidepressant) to date. Some studies have reported a variet y of non-
permanent physical effects such as light-headedness, headache, nausea, diplopia, drowsiness 
and dizziness. These symptoms tend to be benign and again limited to the period of the infusion 
or for a short time following.
Depression trials investigating subanaesthetic doses of ketamine consistently  report transient 
elevations in blood pressure and heart rate during the period of infusion and for up to 80 minutes 
after dosing.
There have been a number of case reports that have linked repeated ketamine 
use to urinary  tract 
problems. These cases have mainly  been reported in the context of recreational ketamine abuse (where 
use is chronic, doses are high, and comorbidity  with other substance use is common).
Finally , there are concerns about the potential for dependence through long-term or repetitive 
ketamine use. However, low -dose usage in a medical setting is less likely  to produce tolerance 
(Katalinic et al 2013 ).
The above risks will be minimized in this trial by clinical observation during and for 2-
4 hours
(i.e. a minimum of 2 hours) after the start of infusion period, as well as extended stay if needed 
based on clinica l judgment at any point during the study . If severe dissociative, psychotic, 
suicidal, or agitated symptoms emerge, clinician -researchers will hospitalize research subjects 
until those clinical adverse events are resolved. If they  persist, or based on clinician- researcher 
judgment or patient preference, those subjects can be dropped from the study  as well at any 
time. Certain benzodiazepines, specificall y lorazepam or alprazolam (asauthorized by country ),
administration also is allowed in the study , within dosage limitations, to manage such possible 
agitation- related effects of ketamine.
The risk of collecting blood may include fainting, pain and/or bruising: rarely , these may be a 
small blood clot or infection at the site of the needle puncture. The risks with an IV infusion 
may include pain, swelling, redness or infection at the injection site. The risk is mitigated by 
selecting professional staff from the clinic experienced in making this ty pe of infusion.
4.5.1 Blood sample volume
A volume smaller 
than a typical blood donation is planned to be collected over a period of 
6weeks, from each subject as part of the study  (representing a total of around 220 ml). 
Additional samples may  be required for safet y monitoring.
Timing of blood sample collection is outlined in the Assessment schedule .
A summary  blood log is provided in the SOM. Instructions for all sample collection, processing, 
storage and shipment information are also available in the SOM and central laboratory manual.
Commercially Confidential Information
Novartis Confidential Page 27
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
5 Population
Approximately  66 subjects (66 completers for the primar y endpoint) diagnosed with treatment -
resistant depression will be randomized to:
In the USA, no ketamine arm will be included. 
It will be competitive recruitment per region.
The investigator or designee must ensure that all subjects being considered for the study  meet 
the following eligibility  criteria.
Subject selection is to be established by checking through all eligibility  criteria at screening. 
Arelevant record (e.g. checklist) of the eligibility  criteria must be stored with the source 
documentation at the stu dy site.
Deviation from an y of the entry  criterion excludes a subject from enrollment into the study .
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following criteria:
1.Signed informed consent must be obtained prior to participation in the study.
2.Male and female subjects, 18 to 65 y ears of age (inclusive) at screening.
3.SCID-based DSM -5 defined major depressive episode at the time of screening .
4.Montgomery -Åsberg Depression Rating Scale (MADRS) score ≥ 24 at screening and
baseline .
5.Failure to respond to two or more antidepressant treatments, where two failed treatments
are of two different antidepressants and at least one of which is in the current depressive
episode, with adequate dose and duration ( ≥ 8 weeks duration, doses defined per agent), as
identified by  the Maudsley Treatment Inventory , and prior ps ychiatric history, assessed b y
the investigator, and further documented b y medical records and/or third party  report
(family , friends, clinician- treaters) where availa ble
6.If patients are taking an y type of psychotropic drugs, a stable dose of ps ychotropic drugs
at screening is defined as no changes in dose or type of antidepressants, antipsy chotics, or
mood stabilizers for at least 2 weeks prior to screening ,if applica ble.
7. No new antidepressant initiated 4 weeks or less before baseline, and 6 weeks or less
before baseline if subject is initiated on fluoxetine
Commercially Confidential Information
Novartis Confidential Page 28
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8. At least one prior clinical depressive episode (recurrent major depressive disorder), as
identified by  prior ps ychiatric history  assessed by  the investigator, and further documented
by medical records and third part y report (famil y, friends, clinician -treaters) where
available.
9.Able to communicate well, and to understand and comply  with study  requirements
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
1.Any current diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder at
screening.
2.Current alcohol or substance use disorder (including marijuana and prescribed
amphetamine) ) meeting DSM-5 criteria, within the past month at baseline. Nicotine and
caffeine use disorders will not be considered as exclusionary .
3.Prior suicidality  caused by  or associated with ketamine, as identified by prior p sychiatric
history  assessed by  the investigator, and augmented by  medical records and third party
report (family , friends, clinician -treaters) where available.
4. Acute serious and/or imminent suicidal ideation and/or intent within the prior 2 weeks, or
any suicide attempt within the prior 4 weeks at screening. Mild to moderate suicidal
ideation, using the Sheehan Suicidal I deation Scale and not meeting the above definition,
is not an exclusion criterion.
5.Use of other investigational drugs within 30 day s or 5 half-lives of randomization,
whichever was longer; or longer if required b y local regulations at baseline.
6.Current pregnancy  or lactation.
7.Positive HI V, H epatitis B or C test.
8.Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre -treatment baseline
9. H istory  of multiple and recurring allergies or allergy  to the investigational
compound/compound class being used in this study.
10.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of
the skin or in-situcervical cancer), tre ated or untreated, within 3 y earsof screening ,
regardless of whether there is evidence of local recurrence or metastases.
11.Women of child- bearing potential, defined as all women physiologicall y capable of
becoming pregnant, unless they are using highly  effective methods of contraception
during dosing and for 1 week after stopping of investigational drug. Highly  effective
contraception methods include:
Total abstinence from heterosexual intercourse (when this is in line with the preferred
and usual lifesty leof the subject). Periodic abstinence (e.g. calendar, ovulation,
symptothermal, post- ovulation methods) and withdrawal are not acceptable methods
of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without
hysterectom y), total hy sterectom y or tubal ligation at least six weeks before taking
study  treatment . In case of oophorectom y alone, only  when the reproductive status of
the woman has been confirmed by  follow up hormone level assessment.
Novartis Confidential Page 29
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Male sterilization (at least 6 months prior to screening). For female subjects on the
study  the vasectomized male partner should be the sole partner for that subject .
Use of oral (estrogen and progesterone), injected or implanted hormonal methods of
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem
(IUS) or other forms of hormonal contraception that ha ve comparable efficacy
(failure rate <1%), for example hormone vaginal ring or transdermal hormone
contraception
In case of use of oral contraception, women should be stable on the same pill for a 
minimum of 3 months before taking study  treatment.
If local regulations deviate from the contraception methods listed above and require more 
extensive measures to prevent p regnancy , local regulations appl y and will be described in 
the Informed Consent Form (I CF).
Women are considered post -menopausal and not of child bearing potential if they have had 
12months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor sy mptoms) or have had surgical bilateral oophorectomy
(with or without hy sterectomy ), total h ysterectomy or tubal ligation at least six weeks ago. 
In the case of oophorectomy  alone, onl y when the reproduc tive status of the woman has 
been confirmed b y follow up hormone level assessment is she considered not of child 
bearing potential. Refer to Section 8.4.3 (Pregnancy and Assessments of Fertility ).
12.Sexually  active males unwilling to use a condom during intercourse while taking
investigational drug and for 1 week after stopping study  treatment . A condom is required
for allsexually  active male participants to prevent them from fathering a child AND to
prevent delivery  of the investigational drug via seminal fluid to their partner. In addition,
male participants should not donate sperm for the time period specified above.
13.History  of hypersensitivity  to any  of the study  treatments or excipients or to d rugs similar
to chemical classes that affect NMDA receptor.
14.Current diagnosis of borderline personality  disorder or antisocial personality  disorder,
based on DSM -5 criteria .
15.Current acute depressive episode lasting longer than two y ears continuously , defin ed as no
two week or longer period where depressive s ymptoms are subsy ndromal in severit y for a
full DSM -5 acute major depressive episode .
16.Considered by  the investigator, for any other reason, to be an unsuitable candidate for the study .
General Note:In the case where a safety  assessment at screening is outside of the range 
specified above, the assessment may be repeated once prior to randomization. If the repeat value 
remains outside of the specified ranges, the subject is excluded from the study .
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible subjects
Novartis Confidential Page 30
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6 Treatment
6.1 Stud y treatment
Details on the requirements for storage and management of study treatment, and inst ructions to 
be followed for subject numbering, prescribing/dispensing and taking study  treatment are 
outlined in the SOM and the Pharmacy  Manual.
6.1.1 Investigational and control drugs
Table 6-1 Overview  of study  medication
Investigational/ Control 
DrugPharmaceutical 
Dosage FormRoute of 
AdministrationPackaging Provided by
MIJ821 20 mg Powder for solution for 
infusionIntravenous use Open label bulk 
supply; vialsNovartis
Placebo 0.9% sodium chloride Intravenous use Open label; infusion 
bagNovartis (EU) 
or locally by 
site(US)
Ketamine 0.5 mg/kg
limiting dose at 40 
mg/infusion for patients 
over 80 kgConcentrate for 
solution for infusion 
Solution for injectionIntravenous use Open label; vials Novartis
The investigational drug MI J821 will be available as lyophilisate in dose strength of 20 mg per 
vial. MIJ821 will be packed and labeled under responsibility  of Novartis and will be supplied 
to the investigator sites. MIJ821 preparation instructions will be provided in the Pharmacy 
Manual.
The active comparator, ketamine will be provided to the investigators by Novartis and the 
placebo (saline 0.9% sodium chloride) will be sourced by Novartis (EU) or locally by site (US).
Details on the requirements for storage and management of study treatment, and instructions to 
be followed for subject numbering, prescribing/dispensing and taking study  treatment are 
outlined in the SOM.
6.1.2 Additional study treatments
No additional treatment bey ond investigational drug and control drug are included in this trial.
6.1.3 Treatment arms/group
Subjects will be assigned at the baseline to one of the following 6-treatment arms in the 
European countries (5 -treatment arms in the USA) in a ratio defined on the Section 5.
Commercially Confidential Information
Novartis Confidential Page 31
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6.2 Other treatment(s)
No additional treatment beyond investigational drug, comparator and placebo are included in 
this trial. 
6.2.1 Concomitant therapy
All medications, procedures and significant non -drug therapies (including physical therap y and  
blood transfusions) administered after the subject was enrolled into the study must be reco rded 
in the concomitant medications / significant non -drug therapies CRF.
The risk of clinical drug -drug interaction of MI J821 and concomitant medications has not been 
completely  assessed. Based on non- clinical investigations and preliminary , qualitative risk 
estimation, appropriate caution is recommended for MIJ821 concomitantly  given with 
inhibitors/inducers of CYP2D6, CYP2C19, and CYP2C8 especially  CYP2D6 inhibitors like 
e.g. bupropion, fluoxetine, paroxetine, and duloxetine.
To minimize the risk of cl inical drug-drug interaction, the following has to be followed:
If patients are treated with an infusion during the morning hours, they  should take their
evening concomitant medications the prior night, but they  should not take their morning
concomitant me dications until at least two hours afte r the end of the infusion.
If patients are treated with an infusion from 12 noon onwards, again they  should not take
their morning concomitant medications until at least two hours after the end of the
infusion.
Each concomitant drug must be individually  assessed against all inclusion criteria. If in doubt 
the investigator should contact the Novartis medical monitor before randomizing a subject or 
allowing a new medication to be started. If the subject is alread y enroll ed, contact Novartis to 
determine if the subject should continue participation in the study .
6.2.1.1 Permitted concomitant therapy  requiring caution and/or action
All allowed concomitant baseline psychotropic medications must remain unchanged throughout 
the study .No new psychotropic drug should be started after baseline. All non-psychotropic 
medications should be changed as little as possible. Certain benzodiazepine s,specifical ly
lorazepam or alprazolam (as authorized by country ),will be allowed for use on an as needed 
basis for emergency  agitation/anxiety , during infusion
,in the morning before infusion 
(details in Section 6.2.1) and2hours post-infusion, not to exceed 2 mg in a 24 hour period. 
Such lorazepam or alprazolam use will be documented as concomitant medication(s).
6.2.2 Prohibited medication
There are no prohibited medications
. Agents that are inhibitors/inducers of CYP2D6, CYP2C19, 
and CYP2C8 will be allowed but will be monitored carefull y by the medical monitor and 
pharmacokinetics will be examined carefull y.Also administration of MIJ821 and such 
CPY450 agents will not be given at the same time range .
Commercially Confidential Information
Novartis Confidential Page 32
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6.2.3 Restriction for study  subjects
For the duration of the study , the subjects should be info rmed and reminded of the restrictions 
outlined in this section.
6.2.3.1 Dietary  restrictions and smoking
No dietary  or smoking restrictions in this study .
6.2.3.2 Other restrictions
If the subject is feeling drunk or dizzy  or if he/she experiences visual disturbances, 
hallucinations, or euphoric mood, then the subject should not drive, use machines or perform 
any other tasks that require his/her attention and good coordination.
6.3 Subject numbering, treatment assignment, randomization
6.3.1 Subject numbering
The subject number assigned to a subject at screening remains the unique identifier for the 
subject throughout the study . For information on subject numbering, please see ‘Subject 
numbering’ section in the SOM.
6.3.2 Treatment assignment, randomization
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A subject 
randomization list will be produced by the IRT provider, or by a  delegate under Novartis 
supervision, using a validated system that automates the random assignment of subject numbers 
to randomization numbers. These randomization numbers are linked to the different treatment 
arms.
Randomization will be stratified b y region, US and European countries .
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Office.
Follow the details outlined in the SOM regarding the process and timing of treatment 
assignment and randomization of subjects .
6.4 Treatment blinding
This i s a subject and investigator -blinded study . Subjects and investigators will remain blinded 
to study  treatment throughout the study , except where indicated below.
The identity  of the treatments will be concealed by the use of study  drugs that are all identi cal 
in packaging, labeling, schedule of administration, appearance, and odor.
Novartis Confidential Page 33
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Site Staff
With the exception of any unblinded site staff identified below, all site staff (including study 
investigator and study  nurse) will be blinded to study  treatment throughout the study .
Unblinding a single subject at site for safety  reasons (necessary  for subject management) will 
occur via an emergency  system in place at the site (see Section 6.6.3) .
Drug product will be supplied in bulk, so an unblinded pharmacist who is independent of the 
study  team will be required in order to maintain the blind. After blinded investigator or his/her 
delegate performs the randomization in NIRTsystem, the unblinded pharmaci st will log into 
the NIRTsystem and see the treatment arm assigned to the randomized subject. 
Appropriate measures must be taken by the unblinded pharmacist to ensure that the treatment 
assignments are concealed from the rest of the site staff.
Sponsor Staff
The following unblinde d sponsor roles are required for this study :
Unblinded field monitor(s)
Unblinded clinical staff managing drug re -supply to site
Unblinded sample anal yst(s) (PK)
The unblinded field monitors are required to review drug accountabilit y and allocation at site. 
The unblinded monitors will be unblinded through unblinded user access to the NIRT system 
and review of source documentation compiled by the unblinded pharmacist, which details 
treatment allocation to individual subjects.
Sponsor clinical staff are requi red to assist in the management and re -supply  of investigational 
drug product. These individuals are not provided with treatment assignment directly , but may 
be unblinded through communication of drug re-suppl y needs via the unblinded site 
pharmacists.
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office), to facilitate analy sis of the samples. The sample analy sts will provide 
the sample data to the study  team under blinded conditions unless otherwise allowed.
The study  statistician will be able to access the treatment assig nments for interim analy ses 
(ifany) and is allowed to share unblinded information with the rest of the clinical team as 
appropriate for internal decision purposes, as outlined in Table 6-2. For example, unblinded 
summaries and unblinded individual data can be shared with the team for interim anal yses.
Study  programmers and other personnel involved in study  data analysis are allowed to 
access 
treatment a ssignment information for the purpose of conducting interim analy ses.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the stud y or the project at the 
time of interim analy ses while the study  is ongoing.
All unblinded personnel will otherwise keep treatment allocation and data or information that 
could unblind other study team members confidential and secure except as described above.
Following final dat abase lock all roles may  be considered unblinded.
Novartis Confidential Page 34
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Table 6-2 Blinding and unblinding plan
Time or Event
Role Randomization 
list generatedTreatment 
allocation & 
dosingSafety  event 
(single subject 
unblinded)
Subjects B B UI
Site staff B B UI
Unblinded site staff e.g. 
pharmacy staffB UI UI
Drug Supply and 
Randomization OfficeUI UI UI
Unblinded sponsor staff 
e.g. for study treatment
re-supply, unblinded
monitor(s), sample
analysts (Bioanalytical
study monitor and
bioanalytical lab
personnel), Translational
Medical expert, study
leads, Clinical Trial
AssociateB UI UI
Unblinded 
Pharmacovigilance 
sponsor staffB B UI
Statistician/statistical 
programmer/ data 
analysts (e.g.
PK)B B UI
Independent committees 
used for assessing 
interim results, if required 
(e.g. DMC)NA NA NA
All other sponsor staff not 
identified above (trial 
team, project team,
management & decision 
board, support functions)B B UI
UI: Allowed to be unblinded on individual subject level
B: Remains blinded
NA: Not applicable to this study
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions in infusions are 
not permitted. If a subject misses a weekl y dose, Novartis medical monitor must be contacted 
to determine if this subject can remain onstudy  and continue with subsequent weekl y infusions . 
Commercially Confidential 
Information
Commercially Confidential Information
Novartis Confidential Page 35
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6.6 Additional treatment guidance
6.6.1 Treatment compliance
The treatment will be administered at the site. The investigator must ensure compliance by 
instructing the study  personnel to deliver the study  treatment exactly  as prescribed and 
bystating that compliance is necessary  for the subject’s safet y and the validity  of the study . 
Compliance will be assessed by the investigator and/or study  personnel at each visit by ensuring 
that the full infusion was effectivel y delivered to the subject. This information should be 
captured in the source document at each visit. All study  treatment dispensed and returned must 
be recorded in the Drug Accountability  Log.
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all subjects 
treated with MI J821, as detailed in the pharmacokinetics Section 8.5.2.
Please refer to the SOM and Pharmacy Manual for further details.
6.6.2 Recommended treatment of adverse events
At present 
there is insufficient information to provide specific recommendations regarding 
treatment of adverse events.
Medication used to treat AEs must be recorded on the Concomitant Medications/Significant 
non-drug therapies CRF.
6.6.3 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
subject safel y. Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  subject who presents with an emergency  
condition. Emergency  treatment code breaks are performed using the Novartis IRT. When the 
investigator contacts the system to break a treatment code for a subject, he/she must provide the 
requested subject identifying information and confirm the necessit y to break the treatment code 
for the subject. The investigator will then receive details of the investigational drug treatment 
for the specified subject and a fax or email confirming this information. The system will 
automatically  inform the Novarti s monitor for the site and the study  team that the code has been 
broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the NIRT at an y time in case of emergency. The investigator will pro vide:
protocol number
study  drug name (if available)
subject number
In addition, oral and written information to the subject must be provided on how to contact 
his/her backup in cases of emergency , or when he/she is unavailable, to ensure that unblinding 
can be performed at an y time.
After an emergency  code break, the subject cannot continue the study .
Novartis Confidential Page 36
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
6.7 Preparation and dispensation
Each stud y site will be supplied with study  drug in packaging as described under Section 6.1.1
(Investigational and control drugs).
For the drug preparation prior to administration, please refer to the Pharmacy  Manual.
A unique medication number is printed on the study medication label.
MIJ821 will be administered to the subject via the followi ng route of administration: i.v. 
Theadministration of the study  treatment will occur at the study  site. See the SOM and 
Pharmacy  Manual for further details.
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnes sed, where required 
by law or regulation), I RB/IEC -approved informed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study  to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
personall y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the 
protocol). The process of obtaining informed consent must be 
documented in the subject source documents.
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
investigator must be agreed by  Novartis before submission to the I RB/IEC.
Informatio n about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed . Any new 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigator notification or 
an aggregate safet y finding. New information might require an update to the informed consent 
and then must be discussed with the subject.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and ag ree that in order 
to participate in the study they  must adhere to the contraception requirements.
Male subjects must be informed that if a female partner becomes pregnant while he is enrolled 
in the study , contact with the female partner will be attempted to request her consent to collect 
pregnancy  outcome information.
Commercially Confidential Information
Novartis Confidential Page 37
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
A copy of the approved version of all consent forms must be provided to Novartis/sponsor after 
IRB/IEC approval.
Refer to the SOM for a complete list of I CFs inclu ded in this study .
8 Visit schedule and assessments
Assessment schedule lists all of the assessments and indicates with an “X”, the visits when they 
are performed. All data obtained from these assessments must be supported in the subject’s 
source documentati on.
Subjects should be seen for all visits/assessments as outlined in the assessment schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontinuation. Subjects who prematurely  discontinu e the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adve rse event and concomitant medications recorded on the CRF.
Commercially Confidential Information
Novartis Confidential Page 38
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Table 8-1 Assessment Schedule
Epoch Screening Treatment
Visit Name Screening Baseline TreatmentFollow 
upEnd 
of 
Study
Visit Numbers11 2 101 102 10312104 105 106 107 108 201 202 299
Days -28 to -2 -1 to 1 1 2 3 8 15 22 29 36 43 57 71
Time (post-dose) - - 0h21h 4h 24h 48h 0h22-4h 0h22-4h 0h22-4h 0h20.67h32-4h 0h22-4h - - -
Informed consent X
Inclusion / 
Exclusion criteriaX X
Medical 
history/current 
medical conditionsX
Alcohol Test and 
Drug Screen S5 S5
Hepatitis and HIV 
ScreenS5
Pregnancy and 
assessments of 
fertility6X7X8X8X8
X7
Demography X
Body Height X
Body W eight X X
Physical 
ExaminationS5S
Vital signs and 
body 
measurementsX X X X X13X X X X13X X13X X13X X X13X X13X
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential InformationCommercially Confidential InformationCCI
Novartis Confidential Page 39
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Epoch Screening Treatment
Visit Name Screening Baseline TreatmentFollow 
upEnd 
of 
Study
Visit Numbers11 2 101 102 10312104 105 106 107 108 201 202 299
Days -28 to -2 -1 to 1 1 2 3 8 15 22 29 36 43 57 71
Time (post-dose) - - 0h21h 4h 24h 48h 0h22-4h 0h22-4h 0h22-4h 0h20.67h32-4h 0h22-4h - - -
Electrocardiogram 
(ECG)X X9X X X
Hematology X X X X X
Clinical Chemistry X X X X X
Urinalysis X X X
PK blood 
collectionX X X X11X XX
Dose 
administration 
(40min)X X X X X X
Structured Clinical 
Interview for DSM -
5S5
Commercially Confidential InformationCCI
Novartis Confidential Page 40
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Epoch Screening Treatment
Visit Name Screening Baseline TreatmentFollow 
upEnd 
of 
Study
Visit Numbers11 2 101 102 10312104 105 106 107 108 201 202 299
Days -28 to -2 -1 to 1 1 2 3 8 15 22 29 36 43 57 71
Time (post-dose) - - 0h21h 4h 24h 48h 0h22-4h 0h22-4h 0h22-4h 0h20.67h32-4h 0h22-4h - - -
Maudsley 
Treatment 
InventoryX
Sydney 
Melancholia 
Prototype IndexX
Melancholia and 
Mixed Depression 
Diagnostic 
ChecklistX
Concomitant 
therapiesX X X9X X X X X X X X X X
Montgomery -
Asberg 
Depression Rating 
ScaleX X X9X X X X X X X X X X X
Bech Rafaelsen 
Melancholia ScaleX X9 X X X X X X X X X X X
CORE 
Melancholia ScaleX X9 X X X X X X X X X X X
Young Mania 
Rating ScaleX X9 X X X X X X X X X X
Clinical Global 
Impression of 
Severity X X9X X X X X X X X X X X
Clinical Global 
Impression of 
ImprovementX X X X X X X X X X
CCI
Novartis Confidential Page 41
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Epoch Screening Treatment
Visit Name Screening Baseline TreatmentFollow 
upEnd 
of 
Study
Visit Numbers11 2 101 102 10312104 105 106 107 108 201 202 299
Days -28 to -2 -1 to 1 1 2 3 8 15 22 29 36 43 57 71
Time (post-dose) - - 0h21h 4h 24h 48h 0h22-4h 0h22-4h 0h22-4h 0h20.67h32-4h 0h22-4h - - -
Clinician 
Administered 
Dissociative 
States ScaleX X9X X X X X X X X X X X
Dissociative 
Experiences Scale 
(DES)X X9X X X X X X X X X X X X
Generic 
Assessment of 
Side Effects in 
Clinical Trials 
(patient self -rating)X X9X X X X X X X X X X X
Hamilton Anxiety 
Rating ScaleX X X
Koukopoulos 
Mixed Depression 
Rating ScaleX X9X X X X X X X X X X X
Sheehan 
Suicidality ScaleX X X9X X X X X X X X X X X
Adverse Events X X X9X X X X X X X X X X X X
Serious Adverse 
EventsX X X9X X X X X X X X X X X X
CCI
Novartis Confidential Page 42
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Epoch Screening Treatment
Visit Name Screening Baseline TreatmentFollow 
upEnd 
of 
Study
Visit Numbers11 2 101 102 10312104 105 106 107 108 201 202 299
Days -28 to -2 -1 to 1 1 2 3 8 15 22 29 36 43 57 71
Time (post-dose) - - 0h21h 4h 24h 48h 0h22-4h 0h22-4h 0h22-4h 0h20.67h32-4h 0h22-4h - - -
Study completion 
informationX
Comments X X X X X X X X X X X X X X
XAssessment to be recorded in the clinical database or received electronically from a vendor
1Visit structure given for internal programming purpose only
2Unless specified in the Assessment Schedule, all assessments a re to be done before start of infusion
5S = assessment to be recorded on source documentation only and will not be entered into the eCRF. If drug screen result is po sitive bu t does not meet 
DSM -5 criteria for substance use disorder, the subject can be enrolled.
6Additional pregnancy testing may be performed at each visit to meet local requirements.
7Serum pregnancy test
8Urine pregnancy test
9Not to be repeated if baseline visit and V101 are conducted on the same day.  
1124 hours after start of the first infusion
12V103 48 hours is an optional visit, however if V103 is conducted, all assessments should be completed.
13Assessments to be conducted once between 2 and 4 hours, and at 6 hours if there is an extended stay.
Commercially Confidential InformationCCI
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 43
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8.1 Screening
It is permissible to re -screen a subject if he/she fails initial screening. However, each case must 
be discussed and agreed with the sponsor on a case-by-case basis. There is no time frame for 
performing the re -screening tests.
In the case where a safety  laboratory  assessment at screening isoutside of the range specified 
in the exclusion criteria, the assessment may be repeated once prior to randomization. If the repeat 
value remains outside of the specified ranges, the subject must be excluded from the study .
If the subject is re -screened, he/she needs to sign again a new informed consent.
Information on what data must be collected for screening failures and further information on 
re-screening is outlined in the SOM.
8.1.1 Information to be collected on screening failures
Information on what data should be collected for screening failures is outlined in the SOM.
8.2 Subject demographics/other baseline characteristics
Subject de mographic and baseline characteristic data will be collected on all subjects. 
Relevant medical history/current medical conditions data will also be collected until signature 
of informed consent. Details are outlined in the SOM.
Hepatitis and HIV test will be performed for samples collected at screening 
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to the informed consent signature.
8.3 Efficacy
8.3.1 Montgomery Asberg Depression Rating Scale
TheMontgomery  Åsberg Depression Rating Scale (MADRS), is a clinician -rated scale 
designed to measure depression severit y and detects changes due to antidepressant treatment: 
the test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 
(severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores 
represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, 
inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts and 
suicidal thoughts (Khan et al 2002). The test exhibits high inter-rater reliability . The typical 
recall period for the MADRS is 7 day s.
Commercially Confidential Information
Novartis Confidential Page 44
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Commercially Confidential Information
Novartis Confidential Page 45
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8.3.4 Appropriateness of efficacy  assessments
The Montgomery  Åsberg Depression Rating Scale (MADRS) now is the standard scale used 
for registration studies of depression. It isrelatively  quick to administer (20 to 30 minutes), 
does not focus predominately  on the somatic symptoms of depression, but rather addresses core 
mood symptoms such as sadness, tension, lassitude, pessimistic thoughts, and suicidal thoughts. 
The MADRS is more sensitive to change from treatment effects over time than the Hamilton 
Depression Rating Scale (HDRS), and has replaced the latter as the gold standard regis tration 
scale for depression. All secondary  scales are psychometricall y validated and reliable as 
measures of subt ypes or symptom features of depressive states. They  are being used to explore 
possible subty pe effects or associated symptom changes to clari fy which aspects of treatment-
resistant depression may improve more or less with the interventions given. Those results will 
be descriptive and used for hy pothesis generation for future studies. 
8.4 Safet y / Tolerability
Safety  assessments are specified below with the Assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to Section 10.1.1.
Assessment Specification
Physical examination A complete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, ly mph nodes, extremities, vascular, and 
neurological. If indicated based on medical history and/or symptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed.
Information for all physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are 
present prior to signing informed consent must be included in the Medical 
History part of the CRF. Significant findings made after first administration 
of investigational drug which meet the definition of an Adverse Event must 
berecorded on the Adverse Event section of the CRF.
Vital sign Vital signs include temperature, BP and pulse measurements. After the 
subject has been sitting for five minutes, with back supported and both 
feet placed on the floor, s ystolic and diastolic blood pressure will be 
measured three times using an automa ted validated device, with an 
appropriately sized cuff. The repeat sitting measurements will be made at 
1 -2 minute intervals and the mean of the three measurements will be 
used. In case the cuff sizes available are not large eno ugh for the 
subject's arm circumference, a sphygmomanometer with an appropriately 
sized cuff may  be used.
Height and weight Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram 
(kg) in indoor clothing, but without shoes) will be measure d.
The methods , assessments, specification, and recording for each assessment will be detailed in 
the SOM.
Novartis Confidential Page 46
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8.4.1 Laboratory  evaluations
All abnormal lab results must be evaluated for criteria defining an adverse event and reported 
as such if the criteria are met. For those lab adverse events, repeated evaluations are mandatory 
until normalization of the result(s) or until the result is no longer considered to be clinicall y 
significant.
Clinically  significant abnormalities must be recorded on the relevant section of the medical 
history  / eCRF page as appropriate.
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of samples and reporting of results by the central laboratory are provided 
to investigator s in the laboratory  manual.
In the case where a laboratory  range is not specified by the protocol, but is outside the reference 
range for the laboratory at screening, a decision regarding whether the result is of clinical 
significance or not shall be made by the Investigator and shall be based, in part, upon the nature 
and degree of the observed abnormalit y. The assessment may be repeated once prior to 
randomization.
In all cases, the Investigator must document in the source documents, the clinical consider ations 
(i.e., result was/was not clinically  significant and/or medicall y relevant) in allowing or 
disallowing the subject to continue in the study .
Clinically  relevant deviations of laboratory test results occurring during or at completion of the 
study  must be reported and discussed with Novartis personnel. The results should be evaluated 
for criteria defining an adverse event and reported as such if the criteria are met.
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. I n case of doubt, Novartis personnel should again be contacted.
Table 8-2 Laboratory  Assessments
Test Category Test Name
Hematology Hemoglobin, hematocrit, red blood cell count, white blood cell count with 
differential (e.g., neutrophils, basophils, eosinophils, monocytes, ly mphocy tes) and 
platelet count will be measured.
Chemistry Albumin, alkaline phosphatase, total bilirubin, bicar bonate/carbon dioxide (CO2), 
calcium, cholesterol, chloride, creatinine, creatinine kinase (CK), GGT, glucose, 
lactic dehydrogenase (LDH), inorganic phosphorus, lipase, am ylase, m agnesium, 
potassium, total protein, AST, ALT, sodium, triglycerides, blood ur ea nitrogen 
(BUN) uric acid. If the total bilirubin concentration is increased above 1.5 times the 
upper limit of normal, direct and indirect reacting bilirubin should be differentiated.
Thyroid Stimulating Hormone (TSH) level will be analyzed as well. In case of 
abnormal TSH value, additional evaluation will be performed (triiodothyronine [T3]
and thryroxine [ T4]).
Urinalysis A midstream urine sample (approximately 30 mL) will be obtained from subjects 
with no urinary catheters, in order to avoid contamin ation with epithelial cells and 
sediments, and allow proper assessments. A semi -quantitative “dipstick” 
evaluation for the following parameters will be performed: specific gravity, pH, 
glucose, protein, bilirubin, ketones, nitrite, leukocy tes and blood. If the dipstick 
result is positive for protein, nitrite, leucoc ytes and/or blood, the sample will be 
sent for microscopic analysis of WBC, RBC and casts.
Novartis Confidential Page 47
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8.4.2 Electrocardiogram (ECG)
Full details of all procedures relating to the ECG collection and reporting arecontained in the 
SOM.
PR interval, QRS duration, heart rate, RR interval, QT interval , QTc .
The Fridericia QT correction formula (QTcF) must be used for clinical decisions.
As applicable, QTcF and QTcB may be calculated in-house. Unless auto- calculated by the ECG 
machine, the investigator must calculate QTcF at the baseline visit to assess eligibility. See the
SOM for additional details.
Clinical significant abnormalities must be reported in the AE CRF.
8.4.3 Pregnancy  and assessments of fertility
A condom is required for all sexually active male participants to prevent them from fathering a 
child AND to prevent delivery of stud y treatment via seminal fluid to their partner while ta king 
investigational drug and for 1 week after stopping study  treatment. In addition, male participants 
should not donate sperm for the time period specified above.
Pregnancy
All pre -menopausal women who are not surgicall y sterile will have pregnancy  testi ng. See the 
Assessment schedule (Table 8-1), for timing of the protocol required pregnancy  testing; 
additional pregnancy  testing may be performed to meet local requirements. A positive urine 
pregnancy  test requires immediate h alt of study  treatment until serum β- hCG is performed and 
found to be negative.
Refer to 
Section 10.1.4 for details on Reporting Pregnancy .
Assessments of fertility
Women are considered post-menopausal and not of child bearing potential if they have had 
12months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age 
appropriate history  of vasomotor symptoms) or have had surgic al bilateral oophorectom y 
(with or without hysterectomy ), total hysterectomy  or tubal ligation at least six weeks before 
taking study  treatment. Inthe case of oophorectomy  alone, only when the reproductive status 
of the woman has been confirmed by follow up hormone level assessment is she considered not 
of child bearing pot ential.
Medical documentation of oophorectom y, hysterectomy , or tubal ligation must be retained as 
source, if available. Subsequent hormone level assessment to confirm the woman is not of child 
bearing potential must also be available as source documentati on in the following cases:
surgical bilateral oophorectomy  without a hy sterectomy
reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.
In the absence of the above medical documentation, FSH testing is required for any female 
subject, regardless of reported reproductive/menopausal status at screening.
Novartis Confidential Page 48
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
Clinical Global Impression
TheClinical Global Impression (CGI) is a 3 item observer -rated scale which measures the 
severit y of symptoms, treatment response and the efficacy of treatments in treatment studies of 
patients with mental disorders (Guy 1976). CGI provides an overall clinician -determined 
summary  measure that takes into account all available information, including a knowledge of 
the patient's history , psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the patient's ability  to function. CGI is rated by an 
experienced clinician who is 
famili ar with the disease under study  and the likely  progression of treatment. The CGI is rated 
without regard to the clinician's belief that any clinical changes are or are not due to medication 
and without consideration of the etiology  of the sy mptoms.
For the study  purpose 2 items will be used : the CGI -Severity , which rates illness severity , and 
the CGI-Improvement, which rates change from the initiation of treatment. The CGI-Severit y 
is rated at all visit except the screening, and the CGI-Improvement at V102 and all following 
visits.
Clinical -Administered Dissociative States Scale
The Clinical -Administered Dissociative States Scale (CADSS) ( Bremner et al 1998) is a 
questionnaire that assesses dissociative effects.
Each item is scored from 0 to 4 and individual scores are to be summed to obtain a total score 
ranging from a minimum of 0 to a maximum of 80. The trained staff administering the scale 
will also note their subjective interpretation of the subject's mental status and overall wellbeing, 
and whether an y findings could be related to study drug.
The CADSS will be administered at all visits except the screening.
Dissociative Experiences Scale
TheDissociative Experiences Scale (DES) (Bernstein andPutnam 1986
) consists of twenty -
eight questions about experiences the subject has experienced in his/her daily  life. The subject 
determines to what degree 
he/she has been facing the situation by selecting a percentage from 
0% (never) to 100% (alway s), with 5% increments in between.
The DES will be administered at all visits except the screening.
Young Mania Rating Scale
The Young Mania Rating Scale (Young et
al1978 ) has 11 items and is based on the patient' s 
subjective report of his/her clinical condition over the previous 48 hours. 
Additional information is based on the clinical observation made during the clinical interview.
There are 4 items that are scored from 0 to 8 (irritability , speech, thought content, and 
disruptive/aggressive behavior) and the remaining items are scored from 0 to 4.
Novartis Confidential Page 49
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
The Young Mania Rating Scale will be administered at all visits except screening and V103.
Bech Rafaelsen Melancholia Scale
Depression scales are used primarily  to me asure changes, for example, to evaluate the efficacy 
of treatment with antidepressants. The Bech -Rafaelsen Melancholia Scale (BRMS) isa 
frequentl y used clinician rating scale to assess the severit y of depression over the past 3 days 
(Bech et al 1975 ). Each of the 11 BRMS items is operationally  defined on a five- point scale 
(0-4); hence, the total score ranges from 0 to 44, higher scores indicating greater severity  of 
depression.
The BRMS will be administered at all visits except screening.
CORE Melancholia Scale
This scale is an 18 item scale, with a 6 item component capturing cognitive impairment and two 
motoric scales capturing psychomotor retardation (7 items) and psychomotor agitation (5 items). 
A cut-off score of 8 or more has been shown to differentiate melancholic from non-melancholic 
depression, with higher scores representing a greater probability  of melancholic depression. 
(Parker and McCraw 2017
). 
The CORE will be administered at all visits except screening.
Maudsley  Treatment Inventory
The Maudsley  Treatment Inventory  (MTI) is a semi -structured instrument that was developed 
to document psychotropic medications and physical therapies used in the treatment of 
depress ion (Fekadu et al 2018). The inventory  is primarily  designed for use in the current 
episode, for which treatment resistance is being rated for. However, the MTI  may  also be used 
for rating treatment resistance for multi ple episodes.
The MTI will be administered at screening.
Generic Assessment of Side effects in Clinical Trials
TheGeneric Assessment of Side Effects (GASE) in Clinical Trials (Rief et
al2009) is an 
instrument to assess side effects in clinical trials. The GASE is a self -rating scale consisting of 
36 items organized by  body  parts. The information collected is based on the past week. GASE 
takes 5 minutes on average to be completed.
The GASE will be administered at all visits except screening.
Structured Clinical Interview for DSM -
5
The Structured Clinical Interview for DSM -5 (SCID -5) is a semi -structured interview guide for 
making the major DSM -5 diagnoses. It is administered by a clinician or trained mental health 
professional who is familiar with the DSM-5 classification and diagnostic criteria. The version 
used for this trial is the Clinician Version SCID-
5-CV.The Structured Clinical Interview for 
DSM -5-Clinician Version guides the clinician step-by-step through the DSM -
5 diagnostic 
process. Interview questions are provided conveniently  along each corresponding DSM -5 
Novartis Confidential Page 50
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
criterion, which aids in rating each as either present or absent. The SCID-5- CV covers the DSM -
5 diagnoses most commonly  seen in clinical settings: depressive and bipolar disorders, 
schizophrenia spectrum and other psychotic disorders, substance use disorders, anxiety  
disorders (panic disorder, agoraphobia, social anxiety  disorder, generalized anxiety  disorder), 
obsessive -compulsive disorder, posttraumat ic stress disorder, attention -deficit/hy peractivity  
disorder, and adjustment disorder. It also screens for 17 additional DSM -5 disorders.
The SCI D-5-CV will be administered at screening .
Sydney  Melancholia Prototype Index
With Sydney  Melancholia Prototy pe Index (SMPI ), this diagnostic index is a one page 
assessment of two basic prototy pes of depression, melancholic versus non-melancholic, each 
with 12 descriptive items. Clinicians are asked to check a box for any item which fits the patients 
description, and then to provide an overall rating about whether the patient more closel y 
approximates one or the other of the two basic prototy pes. ( Parker andMcCraw 2013).
The SMPI  will be administered at screening .
Melancholia and Mixed Depression Diagnostic Checklist
With Melancholia and Mixed Depression Diagnostic Checklist (MMDC), clinicians will be 
asked to fill out a 1 ½ page form which provides a checklist for diagnostic criteria for mixed 
depression according to two differen
t definitions, and a checklist for melancholia.  The first 
mixed depression checklist, created by Koukopoulos, has 8 criteria, which are marked as present 
or absent.  If 3 or more criteria are marked present, then mixed depression would be diagnosed. 
The second mixed depression checklist, created by Angst, lists the 7 criteria for mania from 
DSM -5, which are marked as present or absent.  If 3 or more criteria are marked present, 
excluding an y duration criterion, then mixed depression would be diagnosed. The melancholia 
checklist, created by Ghaemi for this study , has 4 criteria, which are marked as present or absent.  
If 3 or more criteria are marked present, then melancholia would be diagnosed.  All of the above 
checklists occur in the presence of a DSM -5 defined major depressive episode, which is an 
inclusion criterion for this study , and would have been determined beforehand by application 
of the SCI D above.
The MMDC will be administered at screening .
Hamilton Anxiety  Scale
The Hamilton Anxiety  Rating Scale (HAM -A) measures psychic anxiety  and 
somatic anxiety 
symptoms based on a clinical assessment and patient interview. The scale has 14 items, with 
each item rated from 0-4, ranging from not present to very severe. A maximum score of 56 
indicates the mo st severe case. ( Hamilton 1959).
The HAM -A will be administered at baseline, V 106 and V
201.
Novartis Confidential Page 51
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Koukopoulos Mixed Depression Rating Scale
The Koukopoulos Mixed Depression Rating Scale (KMDRS) assesses the excitatory  or mixe d 
nature in patients suffering from a Major Depressive Episode (MDE) as defined by DSM-5 
criteria. This scale is meant to be used in conjunction with another scale that assess typical 
depression and anxiety  symptoms. The scale contains 14 items to be evalu ated by clinical 
assessment and patient interview on symptoms potentially  experienced over the past week. 
Overall score increases with severity  of symptoms and has a maximum score of 51. 
(Sani et al 2018).
The KMDRS wil l be administered at all visits except screening.
8.5.2 Pharmacokinetics
Pharmacokinetic (PK) samples will be collected at the time points defined in the 
Assessment schedule (Table 8-1). Follow instructions outlined in the SOM and inthe 
Bioanal ytical study  specification regarding sample collection, numbering, processing and 
shipment.
In order to better define the PK profile, the timing of the PK sample collect ion may  be altered 
based on emergent data. The number of samples/blood draws and total blood volume collected 
will not exceed those stated in the protocol.
PK samples should be collected in all patients to avoid unblinding. Only the samples from 
patients t
reated with MI J821 will be anal yzed
Pharmacokinetic analytical method(s)
Pharmacokinetic parameters
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 52
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Commercially Confidential Information
Novartis Confidential Page 53
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
9 Study  discontinuation and completion
9.1 Discontinuation
9.1.1 Discontinuation of study treatment
Discontinuation of study  treatment for a subject occurs when study treatment is stopped earlier 
than the protocol planned duration, and can be initiated by either the subject or the investigator.
The investigator must discontinue study  treatment for a given subject if, he/she believes that 
continuation would negatively  impact the subject's well -being.
Study  treatment must be discontinued under the following circumstances:
Subject's decision
Pregnancy
Any situation in which study  participation might result in a safet y risk to the subject
CTC -AE Grade 3 or higher adverse event unless it can be conclusivel y shown that AE is 
not related to study  treatment.
Severe h ypersensitivity  reaction such as anaph ylaxis
Any protocol deviation that results in a significant ris k to subject safet y
Adverse events, abnormal laboratory  values or abnormal test result that indicate a safet y 
risk to the subject
If discontinuation of study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary reaso n for the subject’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLE SS they withdraw 
their consent (see Section 9.1.2 ). Where possible, subjects should return forV299 and complete
the assessments indicated in the Assessment schedule for this visit . If subjects fail to return for 
these assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) should be 
made to contact the subject/pre -designated contact as specified in Section
9.1.3. This contact 
should preferabl y be done according to the study visit schedule.
If the subject cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact should preferabl y be done according to the study visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
new / concom itant treatments
adverse events/Serious Adverse Events
The investigator must also contact the IRT to register the subject’s discontinuation from study  
treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code section.
Novartis Confidential Page 54
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
9.1.1.1 Replacement policy
Subjects who are withdrawn from the study  for reasons other than safety , the decision to replace 
them by  an equal number of newl y enrolled subjects will be taken by the Sponsor.
9.1.2 Withdrawal of informed co nsent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject:
Does not want to participate in the study  anymore
and
Does not allow further collection of personal da ta 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table .
Novartis will continue to keep and use collected study  information (including any data resulting 
from the analy sis of a subject’s samples until the time of withdrawal) according to applicable 
law.
For US: All biological samples not yet analyzed at the time of withdrawal may still be used fo r 
further testing/anal ysis in accordance with the terms of this protocol and of the informed consent 
form.
For EU: All biological samples not yet analyzed at the time of withdrawal will no longer be 
used, unless permitted by applicable law. They  will be stored according to applicable legal 
requirements.
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
docu menting in the source documents steps taken to contact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
Novartis Confidential Page 55
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
9.1.4 Study stopping rules
The study  will be stopped, and no further enrollment will take place pending a full safety  review, 
if any  of the following criteria are met:
At least 5 subjects in an y single treatment arm experience an AE of Grade 3 or higher 
according to t he CTC -AE V5.0 and is potentially  related to study  treatment
Two or more treatment -emergent SAEs, except those that are clearly  and incontrovertibl y 
due to extraneous causes;
The Sponsor considers that the number and/or severity  of AEs justify  putting the study  on 
hold.
The study  may resume following the safet y review, if the Investigator and Sponsor agree it is 
safe to proceed.
9.1.5 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time. 
Reasons for earl y termination:
Unexpected, significant, or unacceptable safety riskto subjects enrolled in the study
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data
Discontinuation of study  drug development
In taking the decision to terminate, Novartis will alway s consider subject welfare and safet y. 
Should early termination be necessary, subjects must be seen as soon as possible and treated as 
a prematurely  withdrawn subject. The investigator may be informed of additional procedures 
to be followed in order to ensure that adequate consideration is given to the protection of the 
subject’s interests. The investigator or sponsor depending on local regulation will be responsible 
for informing IRBs/IECs of the early termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last subject finishes their study  completion visit, and 
any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by the Investiga tor, or in the event of an early study termination decision, the date 
of that decision (e.g. each subject will be required to complete the study in its entiret y and 
thereafter no further study  treatment will be made available to them).
All randomized and/or treated subjects should have a safet y follow -up call conducted 30 days 
after last administration of study  treatment. The information collected is kept as source 
documentation. All SAEs reported during this time period must be reported as described in 
Section 10.1.3 and SOM. Documentation of attempts to contact the subject should be recorded 
in the source documentation.
Novartis Confidential Page 56
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual subject and 
identify ing adve rse events.
Novartis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by non -directive questioning of the subject at 
each visit during the study. Adverse events also may  be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  the following information (as far as possible) 
(if the event is serious refer to Section 10.1.2):
1.The Common Toxicity  Criteria (CTC) AE grade (version 5.0 or higher). A copy  of the 
CTCAE grading will be provided separatel y in the SOM.
Adverse events will be assessed and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) version 5.0
2.its relationship to the study  treatment and o
ther investigational treatment. If the event is 
due to lack of efficacy  or progression of underlying illness (i.e. progression of the study  
indication) the assessment of causalit y will usually be ‘Not suspected’. The rationale for 
this guidance is that the symptoms of a lack of efficacy  or progression of underly ing 
illness are not caused b y the trial drug, they  happen in spite of its administration and/or 
both lack of efficacy  and progression of underly ing disease can only  be evaluated 
meaningfully  by an an alysis of cohorts, not on a single subject
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 10.1.2 for defi nition of SAE) and which 
seriousness criteria have been met
5.action taken regarding with study  treatment.
Novartis Confidential Page 57
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug inte rrupted/withdrawn
6.its outcome .
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosi s whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. Continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator Brochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in subjects with 
the underl ying disease.
Follow the instructions found in the SOM for data capture methodology  regarding AE collection 
for subjects that fail screening.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Novartis Confidential Page 58
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it wer e more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospital ization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition . 
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not wors ened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convu lsions that do 
not result in hospitalization or development of dependency  or abuse (please refer to the 
ICH-E2D Guidelines) .
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All report s of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
10.1.3 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 daysfollowing the last administration of study 
treatment must be reported to Novartis safet y within 24 hours of learning of its occurrence. 
Detailed instructions regarding the submission process and requirements are to be fou nd in the 
investigator folder provided to each site.
Event common in the subject population under study: during studies, the unblinding of 
single SAEs, that are relatively  common in the subject population under study , for SUSAR 
reporting, often does not in crease the understanding of safet y, and can damage the integrity  of 
the blinded nature and analy sis of a study . The study  protocol may then contain a "Table of AEs 
Commonly  Seen in the Subject Population" that are still captured by the investigator as AEs 
and SAEs in the CRF and reported to Novartis for the SAEs, but they  would not be unblinded 
Novartis Confidential Page 59
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
during the course of the study , even if considered "related" to study  treatment by  the reporting 
investigator, nor reported on an expedited basis to regulatory  authorities.
IMPORTANT: To comply  with regulations, all suspected, unexpected, serious adverse 
reactions (SUSARs) occurring in a clinical trial must be reported in an expedited timeframe 
(7or 15 day s) to competent authorities.
Consider the following 2categori es to determine SAE reporting timeframes: 
1.Screen Failures (e.g. a subject who is screened but is not treated or randomized): SAEs 
occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must be reported to Novartis.
2.Randomized OR Treated Subjects: SAEs collected between time subject signs ICF until 
30days after the subject has discontinued or stopped study treatment.
All follow -up information for the SAE including information on complications, p rogression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered comple tely unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study treatment, a Novartis Chief Medical 
Office and Patient Safety  (CMO & PS) Department associate may urgently  require further 
information from the investigator for health authority  reporting. Novartis may  need to issue an 
Investigator Notification (IN) to inform all investigator s involved in any study  with the same 
study  treatment that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day period following the last administration of study  
treatment should only be reported to Novartis Safety  if the investigator suspects a causal 
relationship to study  treatment.
10.1.4 Pregnancy  reporting
To ensure subject safety, each pregnancy occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. The newborns will be followed up f or 3 months after delivery .
Pregnancy  should be recorded and reported by the investigator to the Novartis Chief Medical 
Office and Patient Safety  (CMO&PS) .Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study  treatment any 
pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
Novartis Confidential Page 60
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dose 
Administ ration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see 
Section 10.1.1 and Section 10.1.2, respectivel y.
10.2 Additional Safety  Monitoring
Not applicable.
10.2.1 Liver saf ety monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  paramet er
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 16-
1in Appendix 1for complete definitions of liver laboratory  triggers 
andliver events.
Novartis Confidential Page 61
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Every  liver event defined in Table 16-1 should be followed up by the investigator or designated 
personnel 
at the trial site, as summarized below. Additional details on actions required in case 
of liver events ar
e outlined in Table 16-2. Repeat liver chemistry  tests (ALT, AST, TBL, 
PT/INR, ALP and G -GT) to confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. If results will 
not be available from the central laboratory , then the repeats can also be performed at a 
local laboratory  to monitor the safet y of the subject. If a liver event is subsequently  
reported, an y local liver chemistry tests previously conducted that are associated with this 
event should have results reported on the unplanned local laboratory  CRF
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to Section 9.1.1 ), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should include 
These investigation s can include based on investigator’s discretion: serology  tests, 
imaging and pathology  assessments, hepatologist’s consultancy ; obtaining more 
detailed history  of sy mptoms and prior or concurrent diseases, history  of concomitant 
drug use, exclusion of und erlying liver disease
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.
Refer to the SOM for additional details.
10.2.2 Renal safety  monitoring
The following two categories of abnormal renal laboratory values have to be considered during 
the course of the study :
Serum creatinine increase 
≥ 25% compared to baseline during normal h ydration status
Urine protein- creatinine ratio (PCR) ≥1g/g or ≥100 mg/mmol, OR new onset dipstick 
proteinuria ≥ 3+ OR new onset dipstick h
ematuria ≥ 3+ (after excluding menstruation, 
UTI, extreme exercise, or trauma)
Renal event findings must be confirmed 24 -48 hours after the first assessment.
Every  renal laboratory  trigger or renal event as defined in Table 16-3should be followed up by 
the investigator or designated personnel at the trial site as summarized in Section 16.2.
Refer to the SOM for additional details.
10.2.3 Prospective suicidality assessment
The Sheehan Suicidality  Track ing Scale is a sensitive psychometric tool to prospectivel y assess 
for treatment -
emergent suicidal thoughts and behaviors. The Sheehan Suicidality  Tracking 
Scale (Sheehan -STS) is a prospective rating scale that tracks both treatment -emergent suicidal 
ideat ion and behaviors. The Sheehan -STS is afourteen -item (up to 22) scale that will be 
administered by a clinician. Each item in the Sheehan- STS is scored on a 5-point Likert scale 
Novartis Confidential Page 62
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
(0=not at all, 1=a little, 2=moderatel y, 3=very , and 4=e xtremely ). Data from th e Sheehan -STS 
can be anal yzed as individual item scores, suicidal ideation subscale score (sum of scores from 
items 2, 3, and 4, plus score from item 5 if ≤1), suicidal behavior subscale score (sum of scores 
from items 6, 7a, and 8, plus score from item 5 if >1), and total score.
10.2.4 Data Monitoring Committee
Not required.
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 11 requirements, Investigator site staff will not 
be given access to the EDC system until they have been trained. Automatic validation programs 
check for data discre pancies in the eCRFs and allow modification and/or verification of the 
entered data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (recorded on CRFs) 
(entered into eCRF) is complete, accurate, and that entry and updates are performed in a timel y 
manner. The Investigator must certify that the data entered are complete and accurate
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
11.2 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
fo
r completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Randomization codes and data about all study  treatment (s) dispensed to the subject and all 
dosage changes will be tracked using the Novartis Interactive Response Technology  (NIRT).
Each occurrence of a code break via NIRT will be reported to the clinical team and monitor. 
The code break functionality  will remain available until study  shut down or upon request of 
Novartis.
Novartis Confidential Page 63
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis.Any changes to the database after that time can only be made after 
written agreement b y Novartis development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a 
Novartis/delegated CRO representative will review the protocol and data capture requirements 
(i.e. eSource DDE or eCRFs) with the investigators and their staff. During the study , Novartis 
employ s several methods of ensuring protocol and GCP compliance and the quality /integrity  of 
the sites’ data. The field monitor will visit the site to check the completeness of subject records, 
the accuracy  of data capture / data entry , the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Key study personnel must be available 
to assist the field monitor during these visits. Continuous remote monitoring of each site’s data 
may be performed by a centralized Novartis/delegated CRO/CRA organization. Additionally , 
a central anal ytics organization may  anal yze data & identify  risks & trends for site operational 
parameters, and provide reports to Novartis clinical teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original informed consent fo rm signed by the 
subject (a signed cop y is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require ful l 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
Commercially Confidential Information
Novartis Confidential Page 64
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
12 Data analy sis and statistical methods
The analysis will be conducted on all subject data at the time the trial ends. Any data analysis 
carried out independently by the investigator should be submitted to Novartis before publication 
or presentation.
12.1 Analysis sets
12.2 Subject demographics and other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descr iptively  by treatment group for the FAS and the safet y analysis set.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented. For selected parameters, 
25th and 75th percentiles will also be presented.
Relevant medical histories and current medical conditions at baseline will be summarized by 
system organ class and preferred term, by  treatment group.
12.3 Treatments
Data for stud y drug administration and conco mitant therapies will be summarized by treatment 
group.
Total duration of time on study  drug and reasons for discontinuation of study  drug will be 
summarized by  treatment group.
All available data under safet y analysis set will be used for reporting purpos e.
12.4 Analysis of the primary  endpoint(s)
The primary  aim of this study  is to determine whether MIJ821 display s clinical efficacy  and 
safet y to support further development for treatment- resistant depression.
Commercially Confidential Information
Novartis Confidential Page 65
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
12.4.1 Definition of primary  endpoint(s)
The primary  efficacy  endpoint is change from baseline in the total MADRS score at 24 h after 
single dose administration. The primary  anal ysis will be performed on the ITT set. In addition, 
a similar anal ysis will be performed on the PPS.
The primary  efficacy analysis may be performed once the 24-hour outcome data on MADRS 
score are available from all study  participants. These results may help facilitate further planning 
activities within the MI J821 program.
12.4.2 Statistical model, hypothesis, and method of analy sis
The change from baseline in the total MADRS score at 24 hours after single dose administration 
will be anal yzed using an analy sis of covariance (ANCOVA) model with treatment as a group 
factor and baseline MADRS score as a covariate.
12.4.3 Handling of missin g values/censoring/discontinuations
No imputation of missing data 
will be done for the primary  anal ysis approach.
12.4.4 Sensitivity and Supportive analy ses
Sensitivity analy ses
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 66
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Supportive analy ses
12.5 Analysis of secondary  endpoints
12.5.1 Efficacy  and/or Pharmacody namic sendpoint(s)
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 67
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
12.5.2 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group.
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provided. Inparticular, summary  tables for AEs will summarize only 
on-treatment events, with a start date during the on-treatment period (treatment -emergent AEs).
The on -treatment period lasts from the date of first administration of study  treatment to 30 days 
after the date of the last actual administration of any  study  treatment.
Adverse events
All information obtained on AEs will be display ed by  treatment group and subject.
The number (and percentage) of subjects with treatment emergent AEs (events started after th e 
first dose of study  medication or events present prior to start of double -blind treatment but 
increased in severit y based on preferred term) will be summarized in the following ways:
by treatment, primary  system organ class and preferred term;
by treatme nt, primary  system organ class, preferred term and maximum severity ;
by treatment, Standardized MedDRA Query  (SMQ) and preferred term.
Separate summaries will be provided for study  medication related AEs, death, SAEs, other 
significant AEs leading to discontinuation.
The incidence of psychotomimetic AEs will be tabulated by treatment group, according to 
severit y and relationship to drug.
A subject with multiple AEs within a primary s ystem organ class is only counted once towards 
the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by treatment group, subject, and visit/time and if ranges are 
available, abnormalities as well as clinical notable values will be flagged. Summary  statistics 
will be provided by  treatment and visit/time.
ECG evaluations
All ECG data will be listed by treatment group, subject and visit/time; abnormalities will be 
flagged. Summary  statistics will be provided by  treatment and visit/time.
Commercially Confidential Information
Novartis Confidential Page 68
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Clinical laboratory  evaluations
All laboratory  data will belisted by treatment group, subject, and visit/time and if normal ranges 
are available abnormalities will be flagged. Summary  statistics will be provided by treatment 
and visit/time. Shift tables using the low/normal/high/ (low and high) classification will be used 
to compare baseline to the worst on -treatment value.
Other safety  evaluations
Sheehan suicidality  scalescore data will be listed by treatment, subject and visit/time; abnormalities 
will be flagged. Summary  statistics will be provided by  treatment and visit/time as appropriate .
12.5.3 Pharmacokinetics
Commercially Confidential Information
Novartis Confidential Page 69
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
12.5.4 PK/PD relationshi ps
Exposure -response anal yses will be carried out for relevant endpoints measured in this study.
12.5.5 Patient reported outcomes
Not Applicable.
12.6 Analysis of exploratory  endpoints
12.6.3 Other Exploratory  Endpoints
12.7 Interim analy ses
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 70
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
12.8 Sample size calculation
12.8.1 Primary  endpoint(s )
12.8.2 Secondary  endpoint(s)
Not Applicable.
Commercially Confidential Information
Novartis Confidential Page 71
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declarati on of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subjec t recruitment procedures 
(e.g., advertisements) and any other written information to be provided to subjects. Prior to 
study  start, the investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
Novartis monitors, auditors, Novartis Qualit y Assurance representatives, designated agents of 
Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site 
is requested by a regulatory  authorit y, the investigator must inform Novartis immediately  that 
this request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and posted 
in a publicly  accessible database of clinical trial results, such as the Novartis clinical trial results 
website and all required Health Authority  websi tes (e.g. Clinicaltrials.gov, EudraCT etc.).
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings
13.4 Quali ty Control and Quality  Assurance
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicab le global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The cl inical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes
Novartis Confidential Page 72
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
14 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case by case basis. Under nocircumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemented.
14.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.
Novartis Confidential Page 73
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
15 References
References are available upon request
Aan het Rot M, Collins KA, Murrough JW, et al (2010) Safet y and efficacy of repeated -dose 
intravenous ketamine for treatment -resistant depression. Biol. Psy chiatry  p. 139 -45.
Bech P, Gram LF, Dein E, et al (1975) Quantitative rating of depressive states. Acta Ps ychiatr 
Scand p. 161-70.
Berm an RM, Cappiello A, Anand A, et al (2000) Antidepressant effects of ketamine in 
depressed patients. Biol. Psy chiatry  p. 351-4.
Bernstein EM, Putnam FW (1986) Development, reliability , and validity  of a dissociation 
scale. J. Nerv. Ment. Dis. p. 727-35.
Bremner JD, Kry stal JH, Putnam FW, et al (1998) Measurement of dissociative states with the 
Clinician -Administered Dissociative States Scale (CADSS). J Trauma Stress p. 125-36.
Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underly ing fast -
acting novel antidepressants. Front Pharmacol p. 161.
Cusin C, I onescu DF, Pavone KJ, et al (2017) Ketamine augmentation for outpatients with 
treatment -resistant depression: Preliminary  evidence for two -step intravenous dose escalation. 
Aust N Z J P sychiatry  p. 55 -64.
Eskes P, Spruit M, Brinkkemper S, et al ( 2016) The Sociability  Score: App- based social 
profiling from a healthcare perspective. Computers in Human Behavior , 
59, p. 39 -48
.
Fekadu A, Donocik JG, Cleare AJ (2018) Standardisation framework for the Maudsley  
staging method for treatment resistance in depression. BMC Psy chiatry  p. 100.
Garay  RP, Zarate CA, Charpeaud T, et al (2017) Investigational drugs in recent clinical trials 
for treatment -resistant depression. Expert Rev Neurother p. 593-609.
Guy W (1976) Clinical Global I mpression. ECDEU Assessment Manual for 
Psychopharmacology , revised National Institute of Mental Health, Rockville, MD..
Hamilton M (1959) The assessment of anxiety  states by  rating. Br J Med Psy chol p. 50
-5.
Isometsä ET (2001) Ps ychological autopsy  studies --a review. Eur. Ps ychiatry p. 379
-85.
Katalinic N, Lai R, Somogy i A, et al (2013) Ketamine as a new treatment for depression: a 
review of its efficacy  and adverse effects. Aust N Z J Psy chiatry  p. 710-27.
Khan A, Khan SR, Shankles EB, et al (2002) Relative sensitivity  of the Montgomery -Asberg 
Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global 
Impressions rating scale in antidepressant clinical trials. I nt Clin Psy chopharmacol p. 281-5.
Krystal JH, Karper LP, Seiby l JP, et al (1994) Subanesthetic effects of the noncompetitive 
NMDA antagonist, ketamine, in humans: psy chotomimetic, perceptual, cogni tive, and 
neuroendocrine responses. Arch Gen Ps ychiatry. 51(3) p.199 –214.
Commercially Confidential Information
Novartis Confidential Page 74
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Montgomery  SA, Asberg M (1979) A new depression scale designed to be sensitive to 
change. Br J Psy chiatry  p. 382 -9.
Parker G, McCr aw S (2013). Validation of a new prototy pic measure of melancholia. 
Comprehensive ps ychiatry. 54 (7) p 835-41.
Parker G, McCraw S (2017). The properties and utility  of the CORE measure of melancholia. 
J of Affective Disorders. 207 p128 -135
Practice guideline for the treatment of patients with major depressive disorder, third edition 
(2010).
Preskorn SH (2008) Flat dose -response curves for efficacy : what do they  mean to the 
clinician? J Psy chiatr Pract p. 232
-6.
Price RB, Nock MK, Charney  DS, et al (2009) Effects of intravenous ketamine on explicit and 
implicit measures of suicidality  in treatment -resistant depression. Biol. Psy chiatry p. 522 -6.
Rief W, Glombiewski JA, Barsk yAJ (2009) GASE: Generic Assessment of Side Effects in 
Clinical Trials p. URL : www.gase -scale.com.
Rush AJ, Trivedi MH, Wisniewski SR, et al (2006) Acute and longer -term outcomes in 
depressed outpatients requiring one or several treatment steps: a STAR*D r eport. Am J 
Psychiatry  p. 1905-17.
Sackeim HA (2001) The definition and meaning of treatment -resistant depression. J Clin 
Psychiatry  p. 10-7.
Sani G, Vöhringer PA, Barroilhet SA, et al (2018) The Koukopoulos Mixed Depression 
Rating Scale (KMDRS): An International Mood Network (IMN) validation study  of a new 
mixed mood rating scale. J Affect Disord p. 9 -16.
Singh JB, Fedgchin M, Daly  EJ, et al (2016) A Double -Blind, Randomized, Placebo -
Controlled, Dose- Frequency  Study  of Intravenous Ketamine in Patients With Treatment -
Resistant Depression. Am J Psy chiatry  p. 816-26.
Thakurta RG, Das R, Bhattachary a AK, et al (2012) Rapid response with ketamine on suicidal 
cognition in resistant depression. Indian J Psy chol Med p. 170-5.
Young RC, Biggs JT, Ziegler VE, et al ( 1978) A rating scale for mania: reliability , validity  
and sensitivity . Br J Psy chiatry  p. 429-
35.
Commercially Confidential Information
Novartis Confidential Page 75
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
16 Appendices
16.1 Appendix 1 : Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY 
TRIGGERS3 x ULN < ALT / AST < 5 x ULN
1.5 x ULN < TBL < 2 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN
and TBL > 2 × ULN [mainly conjugated fraction] without notable
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise,
fatigue, abdominal pain, nausea, or vomiting, or rash with
eosinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver
neoplasms TBL: total bilirubin; ULN: upper lim it of normal
Novartis Confidential Page 76
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Table 16-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law caseaDiscontinue the study
treatment immediately
Hospitalize, if clinically
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
ALT or A ST
>5× ULN Discontinue the study
treatment immediately
Hospitalize if clinically
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN and INR > 1.5 Discontinue the study
treatment imm ediately
Hospitalize, if clinically
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN accompanied by
symptomsbDiscontinue the study
treatment immediately
Hospitalize if clinically
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 to ≤ 5 × ULN (subject is
asymptomatic)Repeat LFT within the next
week
If elevation is confirmed,
initiate close observation of
the subjectInvestigator discretion
Monitor LFT within 1 to 4 
weeks
ALP (isolated)
> 2 × ULN (in the absence of
known bone pathology)Repeat LFT within 48
hours
If elevation persists,
establish causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Novartis Confidential Page 77
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Criteria Actions required Follow -up monitoring
TBL (isolated)
> 2 × ULN (in the absence of 
known Gilbert syndrome)Repeat LFT within 48 
hours
If elevation persists, 
discontinue the study  drug 
immediately
Hospitalize if clinically 
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Test for hemoly sis (e.g., 
reticulocytes, haptoglobin, 
uncon jugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN (subject is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation of 
the subjectInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice Discontinue the study 
treatment immediately
Hospitalize the subject
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Any AE potentially indicative of 
a liver t oxicity*Consider study treatment 
interruption or 
discontinuation
Hospitalization if clinically 
appropriate
Establish causality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN 
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) retu rn to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death.
Novartis Confidential Page 78
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
16.2 Appendix 2 : Specific Renal A lert Criteria and A ction s and Event 
Follow -up
Table 16-3 Specific Renal A lert Criteria and A ctions
Renal Event Actions
Confirmed serum creatinine increase
25 –49%Consider causes and possible interventions
Follow up within 2- 5 days
Serum creatinine increase  50 %+
OR if <18 years old, eGFR <35 
mL/min/1.73 m2Consider causes and possible interventions
Repeat assessment within 24- 48h if possible
Consider drug interruption or discontinuation
unless other causes are diagnosed and
corrected
Consider patient hospitalization and
specialized treatment
New onset dipstick proteinuria ≥3+
OR
Protein -creatinine ratio (PCR) ≥ 1g/g 
Cr (or mg/m mol equivalent as 
converted by the measuring 
laboratory)Consider causes and possible interventions
Assess serum albumin & serum total protein
Repeat assessment to confirm
Consider drug interruption or discontinuation
unless other causes are diagnosed and
corrected
New onset hematuria ≥ 3+ on urine 
dipstickAssess & document
Repeat assessment to confirm
Distinguish hemoglobinuria from hematuria
Urine sediment microscopy
Assess sCr
Exclude infection, trauma, bleeding from the
distal urinary tract/bladder, menstruation
Conside r bleeding disorder
+ Corresponds to KDIGO c riteria for Acute Kidney Injury
Additional specialized assessments are available to assess renal function or renal pathology .
Whenever a renal event is identified, a detailed patient history and examination are indicated to 
identify  and potentiall y eliminate risk factors that may have initiate dor contribute dto the event :
Blood pressure assessment (after 5 -minute rest, with an appropriate cuff size)
Signs and sy mptoms like fever , headache, shortness of breath, back or abdominal pain,
dysuria or hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake , voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic
failure, contrast media or other known nephrotoxin administration, or other diseases or
causes, e.g., deh ydration due to delirium , tumor lysis
Novartis Confidential Page 79
Amended Protocol Version 02 (Clean) Protocol No. CMIJ821X2201
Table 16-4 Renal Event Follo w Up
FOLLOW -UP OF RENAL EVENTS
Assess, document and record in CRF
Urine dipstick and sediment microscopy evidence of DIN: crystals, red blood cells
(dysmorphic/glomerular vs. non- dysmorphic/non -glomerular), white blood cells, tubular
epithelial cells
Blood pressure and body weight
Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium),
bicarbonate and uric acid
Urine output
Review and record possible contributing factors to the renal event (co -medications, other 
co-morbid conditions) and additional diagnostic procedures (MRI etc.) in the CRF
Monitor patient regularly (frequency at investigator’s discretion) until -
Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or ACR <300 mg/g Cr )
or
Event stabilization: sCr level with ±10% variability over last 6 months or protein -
creatinine ratio stabilization at a new level with ±50% variability over last 6 months.
Analysis of urine markers in samples collected over the course o f the DIN event